var title_f28_33_29200="Stirrup splint";
var content_f28_33_29200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stirrup splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ankle stirrup splint is applied to prevent inversion or eversion of the ankle, and provides better immobilization for fractures near the ankle than the posterior leg splint. Plaster is applied from below the knee and wrapped around the ankle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29200=[""].join("\n");
var outline_f28_33_29200=null;
var title_f28_33_29201="Alder-Reilly granules";
var content_f28_33_29201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alder-Reilly granules in a patient with mucopolysaccharidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Azurophilic cytoplasmic inclusions (Alder-Reilly granules) in neutrophil of a patient with mucopolysaccharidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anderson, SC, Poulsen, KB. Anderson's Atlas of Hematology. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Wolters Kluwer Health/Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29201=[""].join("\n");
var outline_f28_33_29201=null;
var title_f28_33_29202="Patient information: Dilation and curettage (D and C) (The Basics)";
var content_f28_33_29202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15878\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/11/29874\">",
"         Patient information: Abortion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/25/14738\">",
"         Patient information: Heavy periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/52/17218\">",
"         Patient information: Miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/18/22820\">",
"         Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/24/8578\">",
"         Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/8/28803\">",
"         Patient information: Miscarriage (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dilation and curettage (D and C) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dilation-and-curettage-d-and-c-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31710060\">",
"      <span class=\"h1\">",
"       What is dilation and curettage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dilation and curettage, also called a &ldquo;D and C,&rdquo; is a procedure to remove tissue from the inside of the uterus (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      During a D and C, a doctor first opens (dilates) the cervix. Then he or she puts a surgical tool called a &ldquo;curette&rdquo; through the vagina and cervix, and up into the uterus. He or she uses the curette to scrape and remove tissue from the uterus.",
"     </p>",
"     <p>",
"      A D and C is done in an operating room in a hospital or clinic, and it takes about 15 to 30 minutes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710067\">",
"      <span class=\"h1\">",
"       Why might my doctor do a D and C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might do a D and C to figure out the cause of a symptom or problem.&nbsp;During a D and C, a doctor gets a sample of tissue from your uterus that can be checked for abnormal cells, cancer, or other problems. Women might have a D and C:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        To figure out why they have abnormal bleeding from their uterus",
"       </li>",
"       <li>",
"        If they had an abnormal result from another test, such as a test for uterine cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors can also do a D and C to treat&nbsp;a medical problem or condition. In pregnant or recently pregnant women, a doctor can do a&nbsp;D and C to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Remove any pregnancy tissue that is left in the uterus after a miscarriage &mdash;&nbsp;A miscarriage is when a pregnancy ends on its own.",
"       </li>",
"       <li>",
"        Do an abortion &mdash;&nbsp;An abortion is when a woman chooses to end a pregnancy.",
"       </li>",
"       <li>",
"        Remove an abnormal growth called a \"molar pregnancy\" that has formed in the uterus of a pregnant woman",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In women who are not pregnant, a doctor can do a D and C to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stop severe vaginal bleeding. For example, a woman might have a D and C if her period is too heavy or if she keeps bleeding too much after giving birth.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710074\">",
"      <span class=\"h1\">",
"       What should I do before a D and C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will give you instructions about what to do before a D and C. He or she will probably tell you not to eat or drink anything starting the night before the procedure.",
"     </p>",
"     <p>",
"      Your doctor might give you a device or a medicine to put inside your vagina near your cervix the day before your D and C. The device or medicine can soften the cervix or start to dilate it. Let your doctor or nurse know if you have any trouble getting ready for your D and C.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710081\">",
"      <span class=\"h1\">",
"       What happens during a D and C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will have an IV (needle) put in your arm or hand. Your doctor or nurse will give you fluids and medicines through the IV. Some of these medicines will make you feel relaxed, sleepy, or numb during the procedure.",
"     </p>",
"     <p>",
"      When a doctor does a D and C to find out why a woman is having symptoms, he or she might do another test called a hysteroscopy at the same time. During a hysteroscopy, a doctor puts a small camera inside the uterus to look for problems that could be causing the symptoms. If a woman has a growth in her uterus, a doctor might do a procedure during the D and C to remove it.",
"     </p>",
"     <p>",
"      When a doctor does a D and C to treat a problem or condition, he or she will remove everything inside the uterus. He or she might also scrape away some of the lining of the uterus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710088\">",
"      <span class=\"h1\">",
"       What happens after a D and C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After a D and C, your doctor or nurse will watch you for a few hours to make sure you don&rsquo;t have any problems. Another person should drive you home from the hospital.",
"     </p>",
"     <p>",
"      Your doctor or nurse will tell you when you can do your usual activities again. He or she will also tell you when you can have sex and put things, such as tampons, in your vagina.",
"     </p>",
"     <p>",
"      Most women get their monthly period within 4 to 6 weeks after a D and C.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710095\">",
"      <span class=\"h1\">",
"       What are the side effects of a D and C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common side effects are mild cramping and slight bleeding from the vagina (called spotting). These can last for a few days. If you have pain, you can take a pain-reliever.",
"     </p>",
"     <p>",
"      Other side effects are not as common but can occur after a D and C. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A tear in the uterus",
"       </li>",
"       <li>",
"        Injury to the cervix",
"       </li>",
"       <li>",
"        Infection",
"       </li>",
"       <li>",
"        Areas of scar tissue that form in the uterus",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710102\">",
"      <span class=\"h1\">",
"       Should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you have any of the following problems after your D and C:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever higher than 101&deg;F (38&deg;C)",
"       </li>",
"       <li>",
"        Cramps that last more than 2 days",
"       </li>",
"       <li>",
"        Pain that gets worse",
"       </li>",
"       <li>",
"        Heavy bleeding, or bleeding that lasts more than 2 weeks",
"       </li>",
"       <li>",
"        Fluid coming out of your vagina that is green or smells bad",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31710109\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=see_link\">",
"       Patient information: Miscarriage (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=see_link\">",
"       Patient information: Abortion (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       Patient information: Heavy periods (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"       Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"       Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"       Patient information: Miscarriage (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/33/29202?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15878 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29202=[""].join("\n");
var outline_f28_33_29202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710060\">",
"      What is dilation and curettage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710067\">",
"      Why might my doctor do a D and C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710074\">",
"      What should I do before a D and C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710081\">",
"      What happens during a D and C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710088\">",
"      What happens after a D and C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710095\">",
"      What are the side effects of a D and C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710102\">",
"      Should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31710109\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=related_link\">",
"      Patient information: Abortion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=related_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=related_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=related_link\">",
"      Patient information: Miscarriage (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29203="Septic emboli";
var content_f28_33_29203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sequelae attributable to septic embolization to the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, thick-walled cavity in the lingula with enhancing walls, a left pleural effusion, and partial left lower lobe atelectasis, due to septic embolism in an intravenous drug user.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29203=[""].join("\n");
var outline_f28_33_29203=null;
var title_f28_33_29204="Pathology of malignant pleural mesothelioma";
var content_f28_33_29204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology of malignant pleural mesothelioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Leslie A Litzky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29204/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/33/29204/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesothelioma is a malignant tumor that arises from the mesothelial surfaces of the pleural and peritoneal cavities, the tunica vaginalis, or the pericardium. Eighty percent of all cases are pleural in origin.",
"   </p>",
"   <p>",
"    The pathology of malignant mesothelioma, focusing on the most common form, diffuse pleural malignant mesothelioma, will be reviewed here. The pathology of peritoneal meso and other aspects of pleural mesothelioma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=see_link&amp;anchor=H17#H17\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Histology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link\">",
"     \"Epidemiology of malignant mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC DIFFICULTIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors have made the diagnosis of malignant mesothelioma a particular challenge for most practicing pathologists.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant mesothelioma is rare, except in large referral centers or epidemiologic hotspots.",
"     </li>",
"     <li>",
"      In many cases, only a limited amount of tissue is available for histologic evaluation and special studies. The use of video-assisted thoracoscopy (VAT) biopsies has made this issue less frequent in many practice settings. VAT has greatly improved the size of pleural biopsies and the choice of sampling sites, usually providing enough tissue for definitive diagnosis.",
"     </li>",
"     <li>",
"      Malignant mesothelioma can vary greatly in histologic appearance within any one patient. In addition, a number of other tumors, either originating within the thorax or metastatic from an extrathoracic site, can mimic malignant mesothelioma. There are also a number of benign pleural diseases that may be difficult to separate from pleural malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The widespread availability and use of immunohistochemistry has greatly improved the accuracy of diagnosis in recent years. Molecular studies, although not always available, have also improved diagnostic accuracy in certain situations.",
"   </p>",
"   <p>",
"    Finally, a thorough clinical history that includes a history of prior malignancy as well as past medical diseases and previous therapies is essential to appropriate pathologic examination. High quality radiographic studies and astute radiographic assessment can also make a substantial contribution to pathologic diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GROSS PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early stage malignant pleural mesothelioma presents as multiple small nodules that characteristically are more pronounced on the parietal pleura but can also involve the visceral pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/1\">",
"     1",
"    </a>",
"    ]. As the tumor progresses, these nodules coalesce to form a thickened rind of tumor that fuses the parietal and visceral pleurae.",
"   </p>",
"   <p>",
"    At a more advanced stage, the tumor typically encases the entire lung and extends along the interlobar fissures (",
"    <a class=\"graphic graphic_picture graphicRef62406 \" href=\"UTD.htm?5/16/5377\">",
"     picture 1",
"    </a>",
"    ). This thick rind of tumor can reach diameters of several centimeters or more, despite only minimal invasion of the underlying lung parenchyma. The consistency of the tumor varies from firm to gelatinous.",
"   </p>",
"   <p>",
"    Adjacent structures can be involved at an early stage, with invasion of the chest wall, pericardium, and diaphragm. Seventy percent of patients will have mediastinal lymph node involvement at autopsy. Hematogenous metastases are more common than many physicians assume, particularly to liver, lung, bone, and adrenal glands. Rare localized variants of malignant mesothelioma have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gross appearance is not pathognomonic for mesothelioma and there are other primary and secondary pleural malignancies that can diffusely involve the pleura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mesothelioma is typically classified into three broad histologic subtypes - epithelioid, sarcomatoid, and biphasic (mixed) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there are a number of unusual and rare variants, this categorization has general diagnostic utility in that the differential diagnosis of both benign and malignant lesions, as well as the subsequent immunohistochemical work-up, is guided by this subclassification.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The epithelioid variant is the most common, comprising about 60 percent of all mesotheliomas. Typical histologic appearances of this subtype include tubulopapillary, acinar (glandular), adenomatoid and solid epithelioid patterns (",
"      <a class=\"graphic graphic_picture graphicRef75689 \" href=\"UTD.htm?24/10/24737\">",
"       picture 2",
"      </a>",
"      ). In addition to reactive mesothelial hyperplasia, the differential diagnosis includes metastatic carcinomas and other epithelioid tumors.",
"     </li>",
"     <li>",
"      Sarcomatoid mesotheliomas are composed of malignant spindle cells which may mimic malignant mesenchymal tumors, such as leiomyosarcoma or synovial sarcoma. Desmoplastic mesothelioma, which consists of bland tumor cells between dense bands of collagenous stroma, is considered to be a subtype of sarcomatoid mesothelioma. In addition to fibrous pleurisy, the differential diagnosis includes sarcomatoid carcinoma and other sarcomas.",
"     </li>",
"     <li>",
"      Biphasic or mixed mesotheliomas have epithelioid and sarcomatoid features, but multiple tissue sections or larger samples may be needed to demonstrate both components. Synovial sarcoma, as well as other mixed or biphasic tumors, are typically considered within this differential diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some malignant mesotheliomas are so poorly differentiated and discohesive that lymphomas and non-neoplastic inflammatory disorders must be included within the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Well-differentiated papillary mesothelioma is a rare tumor with a distinctive papillary architecture and bland features that tends to spread superficially without invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/1\">",
"     1",
"    </a>",
"    ]. This type of tumor is more commonly diagnosed in the peritoneum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologic criteria have been described to distinguish reactive mesothelial hyperplasia from epithelioid malignant mesothelioma and fibrous pleurisy from the desmoplastic variant of sarcomatoid mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reactive mesothelial hyperplasia can be caused by infections, connective tissue disease, pulmonary infarct, drug reactions, pneumothorax, subpleural lung carcinomas, surgery, or traumatic injury.",
"     </li>",
"     <li>",
"      Fibrous pleurisy can be the result of asbestos exposure, infection, connective tissue disease, or traumatic injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most reliable criterion for distinguishing reactive mesothelial hyperplasia and fibrous pleurisy from malignancy is the demonstration of stromal invasion. Although the recognition of stromal invasion can be highlighted by positive cytokeratin staining, definitive diagnosis is best achieved by adequate biopsies that include some underlying fibroadipose tissue or, in special circumstances, the pulmonary parenchyma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of immunohistochemical panels is an integral part of the diagnosis of malignant mesothelioma.",
"   </p>",
"   <p>",
"    There is no single marker that has sufficiently high sensitivity and specificity for malignant mesothelioma, and it is, therefore, standard practice for pathologists to employ a panel of markers (both positive and negative). Institutions vary somewhat in their selection of which markers to include, and panels are typically refined as publications appear with studies comparing the utility of different markers. As a general rule, it is recommended that the marker have either sensitivity or specificity greater than 80 percent for the tumors being considered. Marker utility is further subdivided into panels which will be more helpful when the tumor appears to be epithelioid, sarcomatoid, or poorly differentiated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some general principles can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancytokeratin stains are very useful in the diagnosis of mesothelioma and will stain the vast majority of mesotheliomas. If the tumor is pancytokeratin negative, then the screening panel should be broadened to include stains to exclude lymphoma, melanoma, angiosarcoma or epithelioid hemangioendothelioma. There are rare sarcomatoid mesotheliomas which are cytokeratin negative, particularly those with osteosarcomatous differentiation.",
"     </li>",
"     <li>",
"      For epithelioid mesothelioma, common positive immunohistochemical markers that can be used to support a diagnosis of malignant mesothelioma include calretinin,",
"      <span class=\"nowrap\">",
"       CK5/6,",
"      </span>",
"      the Wilms' tumor-I (WT1) antigen (nuclear staining), and D2-40 (podoplanin) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/1\">",
"       1",
"      </a>",
"      ]. Useful markers that are positive in pulmonary adenocarcinoma include MOC-31, BG8, carcinoembryonic antigen, B72.3, Ber-EP4, TTF-1, and CD15 (Leu-M1) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/1\">",
"       1",
"      </a>",
"      ]. When the differential diagnosis is broadened to include other subtypes of lung tumors such as squamous cell carcinoma or metastases from other primary sites such as the kidney or ovary, then the panel must be more specifically directed toward those considerations and the significance of a positive or negative result must be carefully evaluated.",
"     </li>",
"     <li>",
"      For sarcomatoid or biphasic mesothelioma, cytokeratin reactivity does not necessarily differentiate malignant mesothelioma from other sarcomas, particularly if the cytokeratin staining is focal. Multiple cytokeratin antibodies such as",
"      <span class=\"nowrap\">",
"       AE1/3",
"      </span>",
"      or CAM5.2 should be used since cytokeratin expression can be focal, weak or variable [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/7\">",
"       7",
"      </a>",
"      ]. Significant cytokeratin positivity can also be seen in sarcomatoid carcinoma or metastatic sarcomatoid renal cell carcinoma. D2-40 and calretinin are the most reliable of the affirmative mesothelioma markers [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. D2-40 and calretinin do show overlap reactivity with other types of sarcoma, but a positive result may be useful for confirming a diagnosis of sarcomatoid mesothelioma when combined with strong cytokeratin positivity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The possibility of synovial sarcoma can usually be confirmed by molecular testing for the specific X:18 translocation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the number of antibodies suitable for immunohistochemistry on routine formalin-fixed paraffin embedded tissue has increased and included the addition of affirmative mesothelioma markers, immunohistochemistry has largely replaced electron microscopy in its traditional use as the \"gold standard\" for diagnosing malignant mesothelioma.",
"   </p>",
"   <p>",
"    Electron microscopy is still occasionally useful in establishing the diagnosis of well to moderately differentiated epithelioid tumors, when the immunohistochemical results are equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/10\">",
"     10",
"    </a>",
"    ]. The electron microscopic features of malignant mesothelioma have been well characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29204/abstract/11\">",
"     11",
"    </a>",
"    ]. The predominant epithelioid form is composed of polygonal cells with numerous long surface microvilli, prominent desmosomes, and abundant tonofilaments (",
"    <a class=\"graphic graphic_picture graphicRef69168 \" href=\"UTD.htm?5/30/5603\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesothelioma is a malignant tumor that arises from the mesothelial surfaces, most commonly in the pleural cavity, but occasionally in the peritoneal cavity or elsewhere. Malignant mesotheliomas are classified into three major subtypes: epithelioid, sarcomatoid, and biphasic (mixed). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of mesothelioma can be difficult for several reasons. Various metastatic tumors can present in the pleural cavity. Histologically these can look similar to mesotheliomas, as can benign lesions arising in the pleural cavity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnostic difficulties'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunohistochemistry panels are an integral part of the diagnostic approach to these tumors in addition to routine histologic examination. Electron microscopy may be useful when the immunohistochemistry results are equivocal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunohistochemistry'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Electron microscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pathology and Genetics: Tumors of the Lung, Pleura, Thymus, and Heart, IARC, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/2\">",
"      Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol 2005; 29:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/3\">",
"      Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med 2005; 129:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/4\">",
"      Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/5\">",
"      Mangano WE, Cagle PT, Churg A, et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 1998; 110:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/6\">",
"      Husain AN, Colby TV, Ord&oacute;&ntilde;ez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/7\">",
"      Mayall FG, Goddard H, Gibbs AR. The diagnostic implications of variable cytokeratin expression in mesotheliomas. J Pathol 1993; 170:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/8\">",
"      Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/9\">",
"      Ord&oacute;&ntilde;ez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004; 35:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/10\">",
"      Ord&oacute;&ntilde;ez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29204/abstract/11\">",
"      Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruct Pathol 2006; 30:3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4608 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29204=[""].join("\n");
var outline_f28_33_29204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC DIFFICULTIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GROSS PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4608|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/16/5377\" title=\"picture 1\">",
"      Malignant mesothelioma Surgical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/10/24737\" title=\"picture 2\">",
"      Malignant mesothelioma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/30/5603\" title=\"picture 3\">",
"      Malignant mesothelioma EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29205="Sexual problems in men";
var content_f28_33_29205=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sexual problems in men (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/33/29205/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29205/contributors\" id=\"au5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/33/29205/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29205/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/33/29205/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29205/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/33/29205?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SEXUAL PROBLEMS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     For years, men believed that sexual problems were a normal part of growing older. Fortunately, modern medicine and changing attitudes have debunked this myth. As men and their healthcare providers become more comfortable talking about sexual problems and new treatments are developed, there is no reason why men cannot remain sexually active well into their 70s and beyond.",
"    </p>",
"    <p>",
"     Sexual problems in men include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       An inability to acquire or maintain an erection satisfactory for sexual intercourse (also called impotence or erectile dysfunction [ED])",
"      </li>",
"      <li>",
"       A lack of interest in sex (diminished libido)",
"      </li>",
"      <li>",
"       Premature ejaculation",
"      </li>",
"      <li>",
"       Delayed or inhibited ejaculation",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF SEXUAL PROBLEMS IN MEN",
"     </span>",
"    </p>",
"    <p>",
"     Impotence, also referred to as an erectile dysfunction (ED), is the term used to describe men who cannot acquire or maintain an erection during 75 percent of attempts to have sexual intercourse. Men who experience an occasional inability to have an erection and then have no problems later do not have ED.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Limited blood flow",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anything that limits blood flow to the penis can cause impotence. The most common conditions that limit blood flow include cigarette smoking, diabetes, high blood pressure, alcoholism, drug abuse, normal aging, and depression. In addition, many commonly prescribed medications can interfere with male sexual function.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Psychologic causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Depression, performance anxiety, and lack of focus are common causes of psychogenic impotence.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Depression &mdash; Loss of libido and lack of interest in sexual activity are common symptoms of depression. Impotence is, in itself, a depressing experience for any man. Many men choose to accept a decline in sexual function as a natural consequence of aging. Because of shame or embarrassment, they do not discuss this problem with their healthcare provider. This is unfortunate because it is possible to determine the cause(s) of sexual problems, and many options are available to treat erectile dysfunction.",
"      </li>",
"      <li>",
"       Performance anxiety &mdash; Performance anxiety may develop in men who suddenly experience one or more erectile failures during intercourse. The focus of the sexual act shifts from a sensual experience to one filled with anxiety. During later attempts to have sex, the inability to acquire and maintain an erection becomes the focus of the sexual experience.",
"      </li>",
"      <li>",
"       Lack of sensate focus &mdash; Lack of sensate focus refers to the decline in the importance of sex. As a man matures, his interests and concerns expand. If, in the midst of sexual intimacy, he finds himself preoccupied with concerns about money or business matters, his mind will drift and he will lose his sexual focus as well as his ability to concentrate on the sensual experience, both of which are needed to maintain an erection.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DIAGNOSIS OF SEXUAL PROBLEMS IN MEN",
"     </span>",
"    </p>",
"    <p>",
"     In order to determine the cause of the dysfunction, a healthcare provider will take a sexual history, perform a physical examination, and order blood tests to determine if conditions such as diabetes or low testosterone levels are contributing to the sexual problems. Sometimes more specialized tests, such as nocturnal penile tumescence, are done (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Testing'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Sexual history",
"     </span>",
"     &nbsp;&mdash;&nbsp;The clinician will ask the patient personal questions about his sex life to help determine the cause of the condition. It is important that the patient answer the questions honestly and provide as much detail as possible.",
"    </p>",
"    <p>",
"     The clinician will want to know if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Impotence developed slowly or happened suddenly",
"      </li>",
"      <li>",
"       There are erections during the night or in the morning when he first wakes up",
"      </li>",
"      <li>",
"       There are personal problems with a spouse, girlfriend, or sexual partner",
"      </li>",
"      <li>",
"       There are any risk factors for impotence, such as a history of smoking, diabetes, high blood pressure, alcohol or drug abuse, or depression",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to doing a basic physical examination, the clinician may:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Listen to the pulse in the groin blood vessels",
"      </li>",
"      <li>",
"       Perform an eye examination",
"      </li>",
"      <li>",
"       Check the breasts for abnormal swelling, a condition called gynecomastia",
"      </li>",
"      <li>",
"       Examine the penis",
"      </li>",
"      <li>",
"       Check the testicles' size and for any abnormal testicular masses",
"      </li>",
"      <li>",
"       Check a nerve reflex that causes the scrotum to contract when the inner thigh is stroked",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The clinician may order tests to measure levels of testosterone, prolactin, and thyroid hormones in the blood. Abnormally low testosterone, elevated prolactin, and either low or elevated levels of thyroid hormones can cause sexual problems. All men with sexual problems should have blood tests.",
"    </p>",
"    <p>",
"     If a hormonal problem is present, these tests may help to diagnose a more serious problem, such as growth in the pituitary gland or malfunction of the gonads. Even the most experienced clinicians cannot determine hormone levels by asking about the history and performing a physical examination; blood testing is necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Nocturnal penile tumescence",
"     </span>",
"     &nbsp;&mdash;&nbsp;Home nocturnal penile tumescence (NPT) may be recommended. NPT testing measures how many erections a man has during the night, and the quality of the erection (how rigid the penis becomes). Impotent men impaired NPT are considered to have \"organic\" impotence (usually due to blood vessel or nerve disease). Men with normal NPT are considered to have psychogenic impotence. Depending on the results of the NPT test, the clinician may order specialized tests, such as Doppler ultrasonography or angiography, to observe the deep arteries in the penis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      TREATMENTS OF SEXUAL PROBLEMS IN MEN",
"     </span>",
"    </p>",
"    <p>",
"     The goal of treating impotence is to enable a man to achieve and maintain an erection so that he can have sexual intercourse. Depending upon the cause of impotence, treatment may include one or more of the following.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Phosphodiesterase-5 inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Phosphodiesterase-5 (PDE-5) inhibitors work by increasing chemicals that allow the penis to become and remain erect. They help a man to achieve an erection after sexual stimulation, but the medication does not increase sexual desire.",
"    </p>",
"    <p>",
"     PDE-5 inhibitors are effective in restoring potency in about 70 percent of men. They work best in men with psychogenic impotence, though can be used in men with other types of impotence as well. In men with conditions that affect the blood vessels (such as diabetes), PDE-5 inhibitors are effective in about 55 to 60 percent of cases. The success rate in men who have undergone prostate cancer surgery is between 25 and 30 percent.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Sildenafil",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sildenafil (Viagra&reg;) should be taken one hour before planned sexual intercourse. Its effect lasts for about four hours; this refers to the time frame that erection is possible if sexual stimulation occurs, not the duration of the erection. The recommended dose is 50 mg for most men; men over the age of 65 should start with 25 mg. The dose may be increased up to 100 mg if the erection was unsatisfactory or decreased to 25 mg if there are bothersome side effects. Only one dose should be taken per 24 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Vardenafil and tadalafil",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vardenafil (Levitra&reg;) and tadalafil (Cialis&reg;) are also PDE-5 inhibitors used to treat ED. Like sildenafil, men who take vardenafil may have an erection (in response to sexual stimulation) as soon as 30 minutes and for up to four hours after taking a vardenafil tablet (this refers to the time frame that erection is possible if sexual stimulation occurs, not the duration of erection). The recommended dose is 10 mg for most men; men over 65 years should start with 5 mg. The dose may be increased to 20 mg or decreased to 2.5 mg as needed. No more than one dose should be taken per 24 hours.",
"    </p>",
"    <p>",
"     Men who take tadalafil may have an erection within 16 minutes (in response to sexual stimulation) and may be able to experience an erection (in response to sexual stimulation) up to 36 hours after each dose (this refers to the time frame that erection is possible, not the duration of erection). The recommended starting dose is 10 mg for most men. The dose may be increased to 20 mg or decreased to 5 mg as needed. No more than one dose should be taken every 24 hours. Tadalafil can also be taken every day as a low dose pill.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Use of PDE-5 inhibitors",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &mdash; Side effects of PDE-5 inhibitors include headache, flushed (red) skin, indigestion, and dizziness. Sildenafil may cause distorted (blue-tinged) vision. Side effects are generally short-lived and resolve spontaneously.",
"      </li>",
"      <li>",
"       Drug interactions &mdash; Men who use nitrates (nitroglycerin) in any form, either on a regular basis or only as needed for chest pain, should never use PDE-5 inhibitors. Taking PDE-5 inhibitors and nitrates can lead to dangerously low blood pressure. PDE-5 inhibitors do not cause heart attacks.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A man who has used a PDE-5 inhibitor and then develops cardiac problems and requires nitrate medications should NOT use the PDE-5 inhibitor in the future. Men who develop chest pain should contact their healthcare provider or go to an emergency department immediately.",
"    </p>",
"    <p>",
"     Certain medications (including erythromycin, ketoconazole, protease inhibitors, rifampin, phenytoin, and grapefruit juice) can alter the duration of time that sildenafil, vardenafil, and tadalafil remain in the blood stream, which can cause additional side effects. A healthcare provider or pharmacist can provide specific information.",
"    </p>",
"    <p>",
"     Medications such as doxazosin (Cardura&reg;) and terazosin (Hytrin&reg;), used to treat frequent urination and other urinary symptoms caused by an enlarged prostate (called benign prostatic hyperplasia or BPH), should not be taken with any of the PDE-5 inhibitors; the combination of drugs can cause very low blood pressure. However, tamsulosin (Flomax&reg;), also prescribed for bothersome urinary symptoms caused by BPH, is safe to take with tadalafil as it does not cause a dangerous decline in blood pressure. It is not known if tamsulosin is safe to take with sildenafil or vardenafil. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"      \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H696793\">",
"     <span class=\"h3\">",
"      Safety",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not yet proven that sildenafil is safe for these groups:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Men who have had a heart attack, stroke, or life-threatening irregular heartbeats (called arrhythmia) within the last six months",
"      </li>",
"      <li>",
"       Men with untreated low or high blood pressure",
"      </li>",
"      <li>",
"       Men with retinitis pigmentosa, a progressive eye disorder that can lead to blindness",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Resuming sexual activity after a prolonged period of inactivity is similar to beginning a new exercise routine. Men considering a PDE-5 medication should be able to participate in an activity that is approximately equal to the energy required for sex (eg, walking two to four miles per hour on a flat surface). The healthcare provider may recommend exercise treadmill testing to ensure that sexual activity will be safe.",
"    </p>",
"    <p>",
"     Nonarteritic ischemic optic neuropathy or NAION, a condition associated with loss of vision, has been reported in a few men who have taken sildenafil and tadalafil. Most of these cases occurred in men with underlying nerve or blood vessel disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Purchasing medications for erectile dysfunction",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of sources claim to sell medications such as Viagra&reg;, Cialis&reg;, Levitra&reg;, or herbal supplements for erectile dysfunction through the internet or by mail for a reduced cost, often without a prescription. These sources are not known to be safe or reliable, and it is not possible to know whether the pills from these sources contain the actual drug or are counterfeit. Consumers are strongly cautioned to avoid potentially unreliable sources for any medication. Community pharmacies or reputable web-based pharmacies are the most reliable source for all types of medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Penile self-injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;With penile self-injection, the patient injects a medication (alprostadil or papaverine) into the corpora cavernosa (the two chambers of the penis that are filled with spongy tissue). This causes an erection by allowing the blood vessels within the penis to expand so that the penis first swells and then stiffens to create a fully rigid erection (",
"     <a class=\"graphic graphic_figure graphicRef55201 \" href=\"UTD.htm?30/45/31443\">",
"      figure 1",
"     </a>",
"     ). The erection created by penile injection occurs without sexual stimulation (different from the erection that occurs after sildenafil, vardenafil or tadalafil).",
"    </p>",
"    <p>",
"     It takes a lot of training for men to feel comfortable with this type of therapy. Under the guidance of urologists, men are shown how to make the skin on the penis sterile and how to inject the medication properly (",
"     <a class=\"graphic graphic_figure graphicRef63950 \" href=\"UTD.htm?20/56/21378\">",
"      figure 2",
"     </a>",
"     ). Although this treatment works well for erections, many men eventually stop using it because of discomfort from the injections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H173538685\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain is the most common side effect. Men often say that this is the reason they discontinue this type of treatment.",
"    </p>",
"    <p>",
"     There is also a small risk that the penis will remain erect after intercourse. This occurs in 6 percent of men who use alprostadil and about 11 percent of those who use papaverine. Prolonged erection, called priapism, that lasts longer than four to six hours is a medical emergency. A healthcare provider should be contacted immediately. An emergency procedure must be done as soon as possible to empty the blood that is trapped in the penis. An erection that lasts longer than 48 hours often results in scarring of the tissue inside the penis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Intraurethral alprostadil (MUSE)",
"     </span>",
"     &nbsp;&mdash;&nbsp;This treatment uses the same medication (alprostadil) as penile self-injection. Instead of injecting it, the man inserts a device with an alprostadil pellet into the urethra. The urethra is the opening in the center of the penis from which urine flows. The alprostadil is then absorbed into the erectile bodies (corpus cavernosum) to create an erection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H173538692\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects include pain as the blood vessels in the penis widen and swell to create the erection. Problems like prolonged erection and scarring on the outside of the penis are less common than with self-injection therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Vacuum-assisted erection devices",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are several products on the market that use vacuum pressure to draw blood into the penis. A rigid ring is placed at the base of the penis (near the body) to hold the blood inside the penis, allowing it to remain erect. Vacuum devices successfully create erections in as many as 67 percent of patients. Satisfaction with vacuum-assisted erections varies between 25 and 49 percent.",
"    </p>",
"    <p>",
"     Vacuum-assisted devices require that a man be able to hold and pump the unit. It may take a week or more for the device to work effectively. After a man is accustomed to using the device, he can usually create an erection that is rigid enough for penetration and sexual intercourse. He will not be able to ejaculate because the ring that holds blood in the penis also compresses the urethra, preventing semen from exiting. The ability to have an orgasm is not affected by the ring.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Penile prostheses",
"     </span>",
"     &nbsp;&mdash;&nbsp;A penile prosthesis is a device that is surgically implanted and inflates to allow the penis to become erect (",
"     <a class=\"graphic graphic_figure graphicRef51070 \" href=\"UTD.htm?4/11/4272\">",
"      figure 3",
"     </a>",
"     ). Penile prostheses are used less frequently because of the popularity of PDE-5 inhibitors and penile injection therapies. For men who do not respond to these therapies or who find vacuum erection therapy distasteful, penile prostheses are an option.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H173538699\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects of prosthetic devices include the possibility of infection, pain, and mechanical failure. Mechanical failure may require surgically removing the prosthesis and implanting a new one.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Testosterone replacement therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testosterone therapy is prescribed if a man's testes do not make enough of the hormone testosterone. It is of no benefit in improving sexual function in men whose bodies make normal amounts of testosterone. Testosterone levels are determined with blood tests.",
"    </p>",
"    <p>",
"     Men with low blood testosterone levels may have diminished libido (sex drive), erectile dysfunction (impotence), decreased muscle mass, increased fat, and are at increased risk for thinning of the bones (osteoporosis). Treatment is designed to increase a man's testosterone level, libido, erectile function, fat and muscle levels; bone density usually improves as testosterone levels return to normal.",
"    </p>",
"    <p>",
"     Treatment options for testosterone deficient men include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Testosterone injections &mdash; Testosterone injections of either testosterone cypionate (Depo-Testosterone&reg;) or testosterone enanthate (Dela-Testryl&reg;) increase the blood level of testosterone promptly. However, testosterone levels decline quickly; to sustain normal testosterone levels, injections must be given every one to two weeks. Pain at the injection site is the most common side effect.",
"      </li>",
"      <li>",
"       Testosterone gels &mdash; Testosterone gel is applied daily to the skin surface, which allows the testosterone within the gel to be absorbed from the skin into the blood. One gel (Androgel&reg;) is supplied as a foil packet; another (Testim &reg;) is in a small toothpaste-like tube. The gel is applied to the upper arms, near the shoulder, every morning. The gel dries quickly; blood testosterone levels increase within two hours and are stable for 24 hours.",
"       <br/>",
"       <br/>",
"       Because testosterone gel applied to a man's skin surface can be transferred to a female partner's skin, men are cautioned to wear a shirt if sex is planned immediately after applying the gel. The gel is fully absorbed after two hours and the shirt precaution is not necessary after this time.",
"      </li>",
"      <li>",
"       Testosterone skin patch &mdash; The testosterone patch (Androderm&reg;) contains testosterone as well as a chemical enhancer that allows the testosterone to be absorbed through the skin into the blood. The patch is applied in the morning, usually after a shower, to the arm, or back, preferably in an area that has little to no hair (to enhance adhesion); the area where the patch is applied should be rotated. The patch must be changed every day. Side effects include skin irritation and a local rash.",
"      </li>",
"      <li>",
"       Testosterone lozenge &mdash; A testosterone lozenge (Striant&reg;) is placed in the mouth between the cheek and upper gums. It softens and forms a gel that adheres to the gums and remains in place for 12 hours; the testosterone is absorbed through the gums and into the bloodstream. It should be used twice daily and should not be chewed or swallowed. Any remaining gel should be removed before placing the next lozenge. Gum irritation and gingivitis (inflammation of the gums) occurs in a small percentage of men using this treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Psychotherapy and psychoactive medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Depression, anxiety, and distractions can cause erectile dysfunction. Often these problems can be treated using psychological counseling, antidepressant drugs, or both. Sexual therapy is sometimes needed as well.",
"    </p>",
"    <p>",
"     Medications are used to treat both depression and anxiety. They are very effective, though some (especially those of the serotonin reuptake inhibitor (SSRI) class) can cause decreased sex drive and erectile dysfunction. On the other hand, some antidepressant drugs can cause delayed ejaculation, which can be helpful for men with premature ejaculation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Psychological counseling or psychotherapy involves the patient talking to a therapist about his thoughts and concerns. Psychotherapy may be helpful for:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Couples, when one or both partners have a serious medical condition. Anxiety over the safety of sexual activity may be present in people who are ill and his or her partner.",
"      </li>",
"      <li>",
"       Men who suddenly experience one or more erectile failures during attempted intercourse. This is called performance anxiety.",
"      </li>",
"      <li>",
"       Men who are depressed. In this case, psychotherapy may be combined with an antianxiety or antidepressant medication. Almost all antidepressant medications are effective for improving symptoms of depression, but may cause sexual side effects (eg, erectile dysfunction).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Sex therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;This type of therapy is often helpful for men who lack focus or become distracted during sex. Treatment focuses on encouraging both sexual partners to work together and uses structured home exercises to improve concentration.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Yohimbine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Yohimbine was once the only pill available to treat erectile dysfunction. It has been replaced with PDE-5 inhibitors, described above (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Phosphodiesterase-5 inhibitors'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      DISORDERS OF EJACULATION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Premature ejaculation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Premature ejaculation is defined as ejaculation that occurs with minimal sexual stimulation, and which usually occurs before the man is ready. Premature ejaculation causes the penis to become flaccid (limp), making it more difficult to penetrate the partner. It is a fairly common problem, especially in men who are anxious or sexually inexperienced.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Non-drug therapy such as the \"pause and squeeze\" technique is successful for treating premature ejaculation in some men. This is a cumbersome technique that requires the man to stop all sexual stimulation as soon as he feels that ejaculation is near. The man or his partner then applies firm pressure just behind the glans (tip) of the penis. Sexual stimulation may begin again once the feeling of impending ejaculation lessens. It has been recommended that this process be repeated at least 10 times before the man ejaculates. It works for some, but not all, couples; the amount of patience and self-restraint required of both partners is substantial.",
"    </p>",
"    <p>",
"     Antidepressant drugs prolong the time between arousal and ejaculation in some men. These are regarded as the most successful treatment for premature ejaculation. Antidepressants include selective serotonin reuptake inhibitors (SSRIs), such as sertraline and paroxetine. The tricyclic antidepressant clomipramine has been reported to be more effective than SSRIs, although it can cause dry mouth. Men may take these medications on a regular (daily) basis; intermittent use (three to four hours before planned sex) has proven successful for some patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Delayed or inhibited ejaculation",
"     </span>",
"     &nbsp;&mdash;&nbsp;In this condition, men have no difficulty acquiring and maintaining an erection but are unable to climax and ejaculate. This can occur with some antidepressant medications (SSRIs). Emotional factors such as fear of impregnating a partner or anger at the partner can also contribute. Counseling or adjustment of the medication dose is often helpful.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413250138\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27351076\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/20/16706?source=see_link\">",
"      Patient information: Sex as you get older (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=see_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/9/18578?source=see_link\">",
"      Patient information: Low testosterone in men (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27351091\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=see_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38341?source=see_link\">",
"      Erectile dysfunction in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20951?source=see_link\">",
"      Sexual dysfunction in uremic men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=see_link\">",
"      Surgical treatment of erectile dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Urology Care Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.urologyhealth.org/\">",
"      www.urologyhealth.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hormone Health Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/\">",
"      www.hormone.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Sexuality Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://sexuality.about.com/forum\">",
"      file://sexuality.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/33/29205/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H265571\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     The author and UpToDate would like to acknowledge the late Dr. Richard F Spark, who contributed to earlier versions of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/33/29205?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29205/abstract/1\">",
"      McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29205/abstract/2\">",
"      Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29205/abstract/3\">",
"      Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29205/abstract/4\">",
"      Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005; 174:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29205/abstract/5\">",
"      Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract 2003; 9:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_33_29205=[""].join("\n");
var outline_f28_33_29205=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SEXUAL PROBLEMS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF SEXUAL PROBLEMS IN MEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DIAGNOSIS OF SEXUAL PROBLEMS IN MEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           TREATMENTS OF SEXUAL PROBLEMS IN MEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           DISORDERS OF EJACULATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H265571\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/45/31443\" title=\"figure 1\">",
"           Blood flow erection PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/56/21378\" title=\"figure 2\">",
"           Penile self injection PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/11/4272\" title=\"figure 3\">",
"           Inflatable implant PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29206="Initial evaluation and diagnosis of Hodgkin lymphoma in adults";
var content_f28_33_29206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29206/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29206/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29206/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29206/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29206/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/33/29206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the patient with Hodgkin lymphoma (formerly called Hodgkin's disease) is designed to provide information for diagnosis, prognosis, staging, and the selection of treatment. The components of this evaluation are reviewed here. The use of the Ann Arbor and Cotswolds staging systems and the evaluation of the patient during and after therapy are considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should determine the presence or absence, duration, and severity of systemic symptoms which may be associated with Hodgkin lymphoma (HL) such as unexplained fever, sweating, particularly at night, weight loss, pruritus, and alcohol-induced pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that should be determined include performance status, a history of previous malignancy (including other lymphomas), prior treatment with chemotherapy or radiotherapy, previous immunosuppressive illness (eg, HIV), and a family history of HL or other lymphoproliferative, myeloproliferative, or tissue malignancies.",
"   </p>",
"   <p>",
"    Performance status should be recorded initially and at each subsequent visit. The two most commonly used tools are the Karnofsky performance status and the Eastern Cooperative Oncology Group (ECOG) performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A careful and complete physical examination must be performed by a physician experienced in the management of patients with HL. Special attention is directed to the areas in which lymphadenopathy commonly occurs and the number of sites involved should be noted. Waldeyer's ring (tonsils, base of the tongue, nasopharynx) should be examined, especially in patients with high neck disease. The largest mass in each region should be measured and the size of the liver and spleen should be recorded as centimeters below the costal margin in the midclavicular line. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TISSUE BIOPSY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Hodgkin lymphoma (HL) is established by tissue biopsy of representative, appropriately prepared material. A lymph node is preferred with a whole lymph node obtained, if possible. Inguinal nodes should not be biopsied if equally suspicious peripheral nodes are present elsewhere because of frequent inflammation in this area. When the diagnosis of HL is made from biopsy of an extranodal site, confirmation by lymph node biopsy is desirable unless the diagnosis is considered unequivocal. A core needle biopsy, although not ideal, may be adequate in someone with suspected recurrent disease where a prior diagnosis of HL has been made. Details on the morphologic and immunophenotypic changes seen in HL and the staging of HL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bone marrow biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marrow infiltration by malignant cells occurs in up to 6.5 percent of patients with newly diagnosed Hodgkin lymphoma (HL) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/1\">",
"     1",
"    </a>",
"    ]. This is closely associated with advanced clinical stage, occurring in much less than 1 percent of patients with early stage disease (ie, stage IA or IIA) by computed tomography (CT) and virtually no patients with early stage disease by combined positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Available evidence suggests that bone marrow biopsy can be omitted from the staging evaluation of",
"    <strong>",
"     all",
"    </strong>",
"    patients with HL without impacting treatment decisions or patient outcome.",
"   </p>",
"   <p>",
"    The value of bone marrow biopsy in the staging of HL has steadily decreased with the improvement of noninvasive imaging studies and the evolution of treatment paradigms toward the universal incorporation of systemic chemotherapy. The original Ann Arbor staging system developed in 1971 required &ldquo;pathologic staging&rdquo; with bone marrow biopsy, splenectomy, and liver biopsy in order to identify disease that might be cured with radiation therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/5\">",
"     5",
"    </a>",
"    ]. Following the widespread incorporation of CT into staging, the 1989 Cotswold modifications limited unilateral bone marrow biopsy to patients with B symptoms; clinical stage IIB to IV disease; or anemia, leukopenia, or thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/6\">",
"     6",
"    </a>",
"    ]. When a combined",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is performed as part of staging, bone marrow biopsy is no longer required.",
"   </p>",
"   <p>",
"    Observational studies have demonstrated that bone marrow biopsy results do not impact the choice of therapy in patients with HL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/1,4,7\">",
"     1,4,7",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective analysis of 454 patients with newly diagnosed HL who had undergone pretreatment",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      and bone marrow biopsy, focal skeletal",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      lesions and bone marrow biopsy involvement were seen in 18 and 6 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/4\">",
"       4",
"      </a>",
"      ]. No patients with stage I or II HL by",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      had bone marrow involvement. While five patients were converted from stage III to stage IV disease based upon the bone marrow biopsy results alone, none resulted in a change in treatment strategy.",
"     </li>",
"     <li>",
"      In another series of 613 patients with HL staged with CT, bone marrow biopsy influenced the mode of treatment in less than 1 percent of cases, usually in those with B symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not advocate the use of bone marrow biopsy in the staging of patients with HL. Preliminary reports suggest that this approach will also be presented in the next version of the staging and response criteria for HL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of Hodgkin lymphoma is established by biopsy, the following studies should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count including a differential to determine the absolute lymphocyte count",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      Biochemical tests of liver, bone and renal function, including serum alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), albumin, and calcium concentrations",
"     </li>",
"     <li>",
"      Pregnancy test in women with childbearing potential",
"     </li>",
"     <li>",
"      HIV serology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the results of these tests may not contribute directly to staging, they may influence the choice of therapy and guide further investigations to other potential sites of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic investigation should include contrast enhanced computerized tomographic (CT) imaging of the thorax, abdomen, and pelvis. Imaging of the neck, although not absolutely necessary, is being used increasingly. Although three-dimensional estimates of total body tumor burden can be determined from such studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/9\">",
"     9",
"    </a>",
"    ], their clinical utility has yet to be proven.",
"   </p>",
"   <p>",
"    Whole-body positron emission tomography (PET scan) using 18F-fluorodeoxyglucose activity is a more sensitive radiographic modality than CT or gallium scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Although PET scanning is not an absolute indicator of initial disease involvement or of cure after chemotherapy alone, a pre-treatment PET scan is helpful in the initial staging. Studies are in progress to determine the usefulness of PET scanning to guide therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link&amp;anchor=H10#H10\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'PET/CT scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic CT scanning, often performed as part of the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    examination, is recommended in all new patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography has replaced bipedal lymphangiography for the detection of intraabdominal disease because of ease of use and patient convenience. In some cases, however, the specificity may be slightly better with bipedal lymphangiography since distortion of the architecture due to replacement is a reliable sign of tumor involvement. On the other hand, false positive findings with lymphangiography occur in as many as 12 percent of patients due to benign replacement by fat, fibrosis, or reactive hyperplasia, and may be as high as 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/15\">",
"     15",
"    </a>",
"    ]. Now with the common use of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    which allows the independent confirmation of disease with two modalities, there is very little reason to rely on bipedal lymphography. Abnormal findings must be seen on both the CT and PET to confirm involvement in the abdomen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CT scan provides detailed information about the liver and spleen but it is still difficult to reliably diagnose splenic involvement.",
"   </p>",
"   <p>",
"    In one series in which staging laparotomy was the gold standard, the overall accuracy of CT detection for splenic involvement was 58 percent (sensitivity 33 percent, and specificity 76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/16\">",
"     16",
"    </a>",
"    ]. Detecting microscopic involvement in the spleen is now less important as nearly all patients will receive systemic chemotherapy as part of their treatment course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic involvement occurs in approximately 5 percent of cases of Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/17\">",
"     17",
"    </a>",
"    ]. Involvement usually consists of microscopic or small macroscopic foci, making radiologic diagnosis difficult. In one report, for example, the livers of 13 patients with histologically proven hepatic lymphoma were evaluated with both MRI and CT; radiologic testing demonstrated a focal abnormality in only one case [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/18\">",
"     18",
"    </a>",
"    ]. Other studies have found greater sensitivity of MRI for the detection of hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biochemical tests of the liver are also not reliable since they may be abnormal in the absence of histological involvement. For these reasons, the current Cotswolds guidelines recommend that the radiologic diagnosis of hepatic involvement requires the demonstration of multiple focal defects (not cystic or vascular) by at least two imaging techniques, such as CT scanning, isotope scanning, ultrasonography, or MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone disease at presentation is uncommon but occurs at some time in the course of the disease in up to 20 percent of patients with Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/20\">",
"     20",
"    </a>",
"    ]. Bone lesions on plain films are predominantly osteoblastic (sclerotic), although variations may be present in individual cases (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"UTD.htm?21/17/21787\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bone scans should not be used for screening but should be performed in patients with bone or joint pain, an elevated serum alkaline phosphatase not due to liver disease, or suspected areas of bone disease on CT scan or plain film. Bone scans using 99-Tc bound to pyrophosphate or methylene diphosphonate have a sensitivity and specificity exceeding 95 percent in patients with lymphoma and an overall accuracy by site as high as 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29206/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal tract is a common site of extranodal infiltration in non-Hodgkin lymphoma but is rarely involved in Hodgkin lymphoma. If indicated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies with endoscopic biopsy are the preferred choice to confirm suspected involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system involvement with Hodgkin lymphoma is rare. It can present either with intracranial disease or with spinal, extranodal deposits. If suspected, the diagnosis can be readily established with plain radiography, CT scanning or magnetic resonance imaging, and cytology of the cerebrospinal fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline evaluation of cardiac function (eg, cardiac ejection fraction) should be considered if the patient is likely to be treated with an anthracycline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H26#H26\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Noninvasive monitoring of LVEF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline pulmonary function studies (eg, diffusing capacity for carbon monoxide) should be obtained if the patient is to be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Pulmonary'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the patient with Hodgkin lymphoma (formerly called Hodgkin's disease) is designed to provide information for diagnosis, prognosis, staging, and the selection of treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The history should determine the presence or absence, duration, and severity of systemic symptoms which may be associated with Hodgkin lymphoma such as unexplained fever, sweating, particularly at night, weight loss, pruritus, and alcohol-induced pain. Additional inquiries should include prior history of malignancy and associated treatments, immunosuppressive illnesses, and performance status (",
"      <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful and complete physical examination should note the size and location of all masses and the size of the liver and spleen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Hodgkin lymphoma is established by tissue biopsy of representative, appropriately prepared material, preferably an excisional lymph node biopsy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue biopsy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"       \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Available evidence suggests that bone marrow biopsy can be omitted from the staging evaluation of",
"      <strong>",
"       all",
"      </strong>",
"      patients with HL without impacting treatment decisions or patient outcome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bone marrow biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation after diagnosis should include a complete blood count with differential, erythrocyte sedimentation rate, biochemical tests of liver, bone and renal function, pregnancy test in women with childbearing potential, and HIV serology if risk factors are present or in unusual disease presentations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiologic investigation should include contrast enhanced computerized tomographic (CT) imaging of the thorax, abdomen, and pelvis. Whole-body positron emission tomography (PET scan) using 18F-fluorodeoxyglucose activity is a more sensitive radiographic modality than CT alone and a pre-treatment PET scan can be helpful in the initial staging of Hodgkin lymphoma. When available, we suggest obtaining a combined",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan as a measure of disease activity. The CT portion of the combined",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      can often replace the need for a separate contrast chest, abdomen, and pelvic CT scan. Bone scans can be performed in patients with signs or symptoms of bone involvement. Baseline evaluation of cardiac function and pulmonary function should be performed in patients prior to the use of anthracyclines or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , respectively. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/1\">",
"      Macintyre EA, Vaughan Hudson B, Linch DC, et al. The value of staging bone marrow trephine biopsy in Hodgkin's disease. Eur J Haematol 1987; 39:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/2\">",
"      Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002; 119:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/3\">",
"      Vassilakopoulos TP, Angelopoulou MK, Constantinou N, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005; 105:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/4\">",
"      El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30:4508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/5\">",
"      Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/6\">",
"      Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/7\">",
"      Munker R, Hasenclever D, Brosteanu O, et al. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol 1995; 13:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/8\">",
"      Cheson BD. Hodgkin lymphoma: protecting the victims of our success. J Clin Oncol 2012; 30:4456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/9\">",
"      Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001; 19:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/10\">",
"      Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/11\">",
"      Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/12\">",
"      Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/13\">",
"      Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/14\">",
"      Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/15\">",
"      Castellino RA, Billingham M, Dorfman RF. Lymphographic accuracy in Hodgkin's disease and malignant lymphoma with a note on the \"reactive\" lymph node as a cause of most false-positive lymphograms. Invest Radiol 1974; 9:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/16\">",
"      Castellino RA, Hoppe RT, Blank N, et al. Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease. AJR Am J Roentgenol 1984; 143:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/17\">",
"      Kaplan HS, Dorfman RF, Nelsen TS, Rosenberg SA. Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. Natl Cancer Inst Monogr 1973; 36:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/18\">",
"      Weinreb JC, Brateman L, Maravilla KR. Magnetic resonance imaging of hepatic lymphoma. AJR Am J Roentgenol 1984; 143:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/19\">",
"      Weissleder R, Stark DD, Elizondo G, et al. MRI of hepatic lymphoma. Magn Reson Imaging 1988; 6:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/20\">",
"      Braunstein EM. Hodgkin disease of bone: radiographic correlation with the histological classification. Radiology 1980; 137:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29206/abstract/21\">",
"      Anderson KC, Kaplan WD, Leonard RC, et al. Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma. Cancer Treat Rep 1985; 69:1347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4688 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-B869A8C837-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29206=[""].join("\n");
var outline_f28_33_29206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TISSUE BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Spleen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiac function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/17/21787\" title=\"table 2\">",
"      Typical radiographic response in bone to select tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29207="Larynx innervation";
var content_f28_33_29207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Innervation of the larynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Innervation of the larynx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Airway anatomy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29207=[""].join("\n");
var outline_f28_33_29207=null;
var title_f28_33_29208="Pathogenesis, clinical features, and diagnosis of acute cholecystitis";
var content_f28_33_29208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Salam F Zakko, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29208/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/33/29208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the pathogenesis, clinical manifestations, and diagnosis of acute cholecystitis. The treatment of acute cholecystitis, acalculous cholecystitis, and the medical management of gallstone disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=see_link\">",
"     \"Acalculous cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis refers to a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation that is usually related to gallstone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acalculous cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acalculous cholecystitis is clinically identical to acute cholecystitis but is not associated with gallstones, and usually occurs in critically ill patients. It accounts for approximately 10 percent of cases of acute cholecystitis and is associated with high morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=see_link\">",
"     \"Acalculous cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cholecystitis is the term used by the pathologist to describe chronic inflammatory cell infiltration of the gallbladder seen on histopathology. It is almost invariably associated with the presence of gallstones and is thought to be the result of mechanical irritation or recurrent attacks of acute cholecystitis leading to fibrosis and thickening of the gallbladder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Its presence does not correlate with symptoms since patients with extensive chronic inflammatory cell inflammation may have only minimal symptoms and there is no evidence that chronic cholecystitis increases the risk for future morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/5\">",
"     5",
"    </a>",
"    ]. Hence, the clinical significance of this entity is questionable. Some authors use the phrase \"chronic cholecystitis\" when referring to gallbladder dysfunction as a cause of abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/6\">",
"     6",
"    </a>",
"    ]. It is more appropriate in this instance to refer to the condition based on the disorder present, such as pain due to gallstone disease, pain due to biliary dyskinesia (which is attributed to sphincter of Oddi dysfunction), or pain due to gallbladder motor dysfunction (also called gallbladder dyskinesia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to biliary colic, the development of acute cholecystitis is not fully explained by cystic duct obstruction alone. Studies in animals have demonstrated that ligation of the cystic duct does not result in acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, acute cholecystitis can be produced experimentally by blockade of the cystic duct followed by deliberate irritation of the gallbladder mucosa (either mechanically with an indwelling catheter or by infusion of an irritant).",
"   </p>",
"   <p>",
"    One such irritant used in experimental models, lysolecithin, is produced from lecithin, a normal constituent of bile. The production of lysolecithin from lecithin is catalyzed by phospholipase A, which is present in gallbladder mucosa. This enzyme may be released into the gallbladder following trauma of the gallbladder wall from an impacted gallstone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/8\">",
"     8",
"    </a>",
"    ]. Supporting this hypothesis is the observation that lysolecithin (normally absent in bile) is detectable in gallbladder bile in patients with acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once inflammation of the gallbladder begins, additional inflammatory mediators are released, further propagating gallbladder inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/10\">",
"     10",
"    </a>",
"    ]. Prostaglandins, which are involved in gallbladder contraction and fluid absorption, probably play a central role in this process. In experimental models using human gallbladder tissue, the main prostaglandins synthesized by inflamed human gallbladder microsomes were prostaglandin E2 and 6-keto-prostaglandin F1 alpha, the concentrations of which were increased four times above normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/11\">",
"     11",
"    </a>",
"    ]. The prostaglandin hypothesis is supported by the observation that prostaglandin inhibitors relieve biliary colic and can reduce intraluminal cystic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection of bile within the biliary system probably has a role in the development of cholecystitis; however, not all patients with cholecystitis have infected bile. This observation was illustrated in a study of 467 subjects in whom bile samples were obtained from the gallbladder and common bile duct for aerobic and anaerobic culture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with a variety of hepatobiliary diseases and a healthy control group were included. Patients with gallstones, acute cholecystitis, and hydropic gallbladder had similar rates of positive cultures in the gallbladder and common bile duct, ranging from 22 to 46 percent; cultures were generally sterile in healthy subjects. The main species isolated were Escherichia coli, Enterococcus, Klebsiella, and Enterobacter.",
"   </p>",
"   <p>",
"    Histologic changes of the gallbladder in acute cholecystitis can range from mild edema and acute inflammation to necrosis and gangrene. Occasionally, prolonged impaction of a stone in the cystic duct can lead to a distended gallbladder that is full of colorless, mucoid fluid. This condition, known as a mucocele with white bile (hydrops), is due to the absence of bile entry into the gallbladder and absorption of all the bilirubin within the gallbladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute cholecystitis typically complain of abdominal pain, most commonly in the right upper quadrant or epigastrium. The pain may radiate to the right shoulder or back. Characteristically, acute cholecystitis pain is steady and severe. Associated complaints may include nausea, vomiting, and anorexia. There is often a history of fatty food ingestion about one hour or more before the initial onset of pain.",
"   </p>",
"   <p>",
"    Prolonged or recurrent cystic duct blockage can progress to total obstruction causing acute cholecystitis. An episode of prolonged right upper quadrant pain (greater than four to six hours), especially if associated with fever, should arouse suspicion for acute cholecystitis as opposed to an attack of simple biliary colic. Symptoms that are not suggestive of a biliary etiology include fatty food intolerance not in the form of pain, nausea not in association with pain, pain only a few minutes after a meal, irregular bowel habits, or belching [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute cholecystitis are usually ill appearing, febrile, and tachycardic, and lie still on the examining table because cholecystitis is associated with true local parietal peritoneal inflammation that is aggravated by movement. Abdominal examination usually demonstrates voluntary and involuntary guarding.",
"   </p>",
"   <p>",
"    Elicitation of \"Murphy's sign\" may be a useful diagnostic maneuver. While palpating the area of the gallbladder fossa just beneath the liver edge, the patient is asked to inspire deeply, causing the gallbladder to descend toward the examining fingers. Patients with acute cholecystitis commonly experience increased discomfort and may have an associated inspiratory arrest. In one study, using cholescintigraphy as the gold standard, the sensitivity and specificity of a positive Murphy's sign were 97 and 48 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/18\">",
"     18",
"    </a>",
"    ]. The sensitivity of Murphy's sign may be diminished in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left untreated, symptoms of cholecystitis may abate within 7 to 10 days. However, complications can occur at alarmingly high rates, so urgent plans for treatment must be entertained in patients with suspected acute cholecystitis. The most common complication is the development of gallbladder gangrene (up to 20 percent of cases) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86863 \" href=\"UTD.htm?34/62/35810\">",
"     image 1",
"    </a>",
"    ) with subsequent perforation (2 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gangrene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gangrenous cholecystitis is the most common complication of cholecystitis, particularly in older patients, diabetics, or those who delay seeking therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/20\">",
"     20",
"    </a>",
"    ]. The presence of a sepsis-like picture in addition to the other symptoms of cholecystitis should suggest the diagnosis, but gangrene may not be suspected preoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforation of the gallbladder usually occurs after the development of gangrene. It is often localized, resulting in a pericholecystic abscess (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86867 \" href=\"UTD.htm?31/26/32168\">",
"     image 2",
"    </a>",
"    ). Less commonly, perforation is free into the peritoneum, leading to generalized peritonitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86865 \" href=\"UTD.htm?37/16/38150\">",
"     image 3",
"    </a>",
"    ). Such cases are associated with a high mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cholecystoenteric fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cholecystoenteric fistula may result from perforation of the gallbladder directly into the duodenum or jejunum. Fistula formation is more often due to long standing pressure necrosis from stones than to acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gallstone ileus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passage of a gallstone through a cholecystoenteric fistula may lead to the development of mechanical bowel obstruction, usually in the terminal ileum (gallstone ileus) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80522 \" href=\"UTD.htm?1/37/1618\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26598?source=see_link\">",
"     \"Gallstone ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Emphysematous cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysematous cholecystitis is caused by secondary infection of the gallbladder wall with gas-forming organisms (such as Clostridium welchii) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56763 \" href=\"UTD.htm?41/57/42899\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Other organisms that may be isolated include Escherichia coli (15 percent), staphylococci, streptococci, Pseudomonas, and Klebsiella [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients are more commonly men in their fifth to seventh decade [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/24\">",
"     24",
"    </a>",
"    ], and approximately one-third to one-half are diabetic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Gallstones are present in about one-half of patients.",
"   </p>",
"   <p>",
"    Like other patients with acute cholecystitis, patients with emphysematous cholecystitis usually present with right upper quadrant pain, nausea, vomiting, and low-grade fever. Peritoneal signs are usually absent, but crepitus in the abdominal wall adjacent to the gall bladder may rarely be detected. When such crepitus is present, it is an important clue to the diagnosis. Mild to moderate unconjugated hyperbilirubinemia may be present (caused by hemolysis induced by clostridial infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"    </a>",
"    .) The ultrasound report may erroneously note the presence of \"overlying bowel gas making adequate visualization of the gallbladder difficult\" while in reality this reflects air in the wall of the gallbladder.",
"   </p>",
"   <p>",
"    Emphysematous cholecystitis often heralds the development of gangrene, perforation, and other complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In a review of 20 patients, gallbladder perforation occurred in seven, pericholecystic abscess in nine, and bile peritonitis in three [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis should be suspected when a patient presenting with the clinical manifestations outlined above is found to have gallstones on an imaging study. However, the mere presence of gallstones is not sufficient for making a diagnosis of acute cholecystitis, since asymptomatic cholelithiasis is a common condition in the general population. Thus, confirmation of the diagnosis must be based upon a combination of physical findings, laboratory studies, and imaging tests (",
"    <a class=\"graphic graphic_algorithm graphicRef50032 \" href=\"UTD.htm?30/12/30912\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The basis for this recommendation was underscored in a systematic review that focused on 17 studies examining the role of the history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory tests in adults with abdominal pain or suspected acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/27\">",
"     27",
"    </a>",
"    ]. No single clinical or laboratory finding was sufficiently accurate to rule-in or rule-out the diagnosis. The most accurate physical findings were a positive Murphy sign (positive likelihood ratio (LR) 2.8, 95% CI 0.8 to 8.6) and right upper quadrant tenderness (negative LR 0.4, 95% CI 0.2 to 1.1). On the other hand, the correct diagnosis (confirmed at surgery) was frequently achieved by the clinical impression in which the history, physical examination, laboratory results, and radiologic findings were considered together (LR ranging from 25 to 30).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation should include a white blood cell count with differential, which often shows leukocytosis with an increased number of band forms (ie, a left shift). Elevation in the serum total bilirubin and alkaline phosphatase concentrations are",
"    <strong>",
"     not",
"    </strong>",
"    common in uncomplicated cholecystitis, since biliary obstruction is limited to the gallbladder; if present, they should raise concerns about complicating conditions such as cholangitis, choledocholithiasis, or the Mirizzi syndrome (a gallstone impacted in the distal cystic duct causing extrinsic compression of the common bile duct) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86878 \" href=\"UTD.htm?2/37/2642\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=see_link\">",
"     \"Mirizzi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there have been reports of mild elevations in serum aminotransferases and amylase, along with hyperbilirubinemia and jaundice, even in the absence of these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/28\">",
"     28",
"    </a>",
"    ]. These abnormalities may be due to the passage of small stones, sludge, or pus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination alone often cannot determine which of the abdominal viscera is the source of inflammation and pain. Thus, patients presenting with clinical features suggestive of acute cholecystitis should undergo imaging tests to confirm the diagnosis. Ultrasonography is usually the first test obtained and can often establish the diagnosis. Nuclear cholescintigraphy may be useful in cases in which the diagnosis remains uncertain after ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of stones in the gallbladder in the clinical setting of right upper quadrant abdominal pain and fever supports the diagnosis of acute cholecystitis but is not diagnostic. Additional sonographic features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gallbladder wall thickening (greater than 4 to 5 mm) or edema (double wall sign) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83042 \" href=\"UTD.htm?4/57/5015\">",
"       image 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A \"sonographic Murphy's sign\", which is similar to the Murphy's sign elicited during abdominal palpation, except that the positive response is observed during palpation with the ultrasound transducer. This is more accurate than hand palpation because it can confirm that the gallbladder is being pressed by the imaging transducer when the patient displays the inspiratory arrest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have evaluated the accuracy of ultrasonography in the diagnosis of acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/27,29-34\">",
"     27,29-34",
"    </a>",
"    ]. A particularly informative systematic review summarized the results of 30 studies of ultrasonography for gallstones and acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/31\">",
"     31",
"    </a>",
"    ]. Adjusted sensitivity and specificity for diagnosis of acute cholecystitis were 88 percent (95% CI 0.74 to 1.00) and 80 percent (95% CI 0.62 to 0.98), respectively.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of ultrasonography for detection of gallstones are in the range of 84 (95% CI 0.76 to 0.92) and 99 (95% CI 0.97 to 1.00) percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/31\">",
"     31",
"    </a>",
"    ]. Ultrasonography may not detect small stones or sludge as illustrated by a study that compared ultrasonography with direct percutaneous mini-endoscopy in patients who had undergone topical gallstone dissolution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/35\">",
"     35",
"    </a>",
"    ]. Ultrasonography was negative in 12 of 13 patients in whom endoscopy demonstrated 1 to 3 mm stones or fragments (",
"    <a class=\"graphic graphic_picture graphicRef65714 \" href=\"UTD.htm?13/22/13679\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cholescintigraphy (HIDA scan)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholescintigraphy (generically referred to as a HIDA scan) is indicated if the diagnosis remains uncertain following ultrasonography. This nuclear medicine examination uses a technetium labeled hepatic iminodiacetic acid (HIDA), which is injected intravenously and is then taken up selectively by hepatocytes and excreted into bile. If the cystic duct is patent, this agent will enter the gallbladder, leading to its visualization without the need for concentration. The HIDA scan is also useful for demonstrating patency of the common bile duct and ampulla. Visualization of contrast within the common bile duct, gallbladder, and small bowel occurs within 30 to 60 minutes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59241 \" href=\"UTD.htm?8/52/9024\">",
"     image 8",
"    </a>",
"    ). The test is positive if the gallbladder does not visualize, which is invariably due to cystic duct obstruction, usually from edema associated with acute cholecystitis or an obstructing stone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86879 \" href=\"UTD.htm?27/13/27856\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cholescintigraphy has a sensitivity and specificity of approximately 97 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/31,34,36\">",
"     31,34,36",
"    </a>",
"    ]. Cystic duct obstruction with a stone or tumor in the absence of acute cholecystitis can cause a false positive test. Other conditions that can cause false positive results in which the gallbladder does not visualize despite a nonobstructed cystic duct include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe liver disease, which may lead to abnormal uptake and excretion of the tracer.",
"     </li>",
"     <li>",
"      Fasting patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      , in whom the gallbladder is already maximally full due to prolonged lack of stimulation.",
"     </li>",
"     <li>",
"      Biliary sphincterotomy, which may result in low resistance to bile flow, leading to preferential excretion of the tracer into the duodenum without filling of the gallbladder.",
"     </li>",
"     <li>",
"      Hyperbilirubinemia, which may be associated with impaired hepatic clearance of iminodiacetic acid compounds. Newer agents commonly used in cholescintigraphy (diisopropyl and m-bromothymethyl iminodiacetic acid) have generally overcome this limitation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    False negative results are uncommon, since most patients with acute cholecystitis have obstruction of the cystic duct. When they occur, they may be due to incomplete cystic duct obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Morphine cholescintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A modified version of the HIDA scan has been described, in which patients are given intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    during the examination. Morphine increases sphincter of Oddi pressure, thereby causing a more favorable pressure gradient for the radioactive tracer to enter the cystic duct. This modification is thought to be particularly useful in critically ill patients, in whom standard HIDA scanning may be associated with false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, the test has not been well standardized, and has not gained wide acceptance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Magnetic resonance cholangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance cholangiography (MR cholangiography) is a noninvasive technique for evaluating the intrahepatic and extrahepatic bile ducts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86864 \" href=\"UTD.htm?5/5/5206\">",
"     image 10",
"    </a>",
"    ). Its role in the diagnosis of acute cholecystitis was evaluated in a series that included 35 patients with symptoms of acute cholecystitis who underwent both ultrasound and MR cholangiography prior to cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/6\">",
"     6",
"    </a>",
"    ]. MR cholangiography was superior to ultrasound for detecting stones in the cystic duct (sensitivity 100 versus 14 percent) but was less sensitive than ultrasound for detecting gallbladder wall thickening (sensitivity 69 versus 96 percent). At the present time its role in the diagnosis of acute cholecystitis should remain within clinical trials. However, MRCP is appropriate if there is concern that the patient may have a stone in the common bile duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal computed tomography (CT) is usually unnecessary in the diagnosis of acute cholecystitis, although it can easily demonstrate gallbladder wall edema associated with acute cholecystitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77336 \" href=\"UTD.htm?12/55/13173\">",
"     image 11",
"    </a>",
"    ). Other CT findings include pericholecystic stranding and fluid, and high-attenuation bile [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, CT may fail to detect gallstones because many stones are isodense with bile (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86866 \" href=\"UTD.htm?9/63/10233\">",
"     image 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. CT can be useful when complications of acute cholecystitis (such as emphysematous cholecystitis or gallbladder perforation) are suspected or when other diagnoses are considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Oral cholecystography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral cholecystography has",
"    <strong>",
"     no",
"    </strong>",
"    role in the diagnosis of acute cholecystitis since it cannot show gallbladder wall edema and requires days to complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest initial challenge in the diagnosis of acute cholecystitis is distinguishing it from the more benign condition of biliary colic. Biliary colic is usually caused by the gallbladder contracting in response to a fatty meal, pressing a stone against the gallbladder outlet or cystic duct opening, and leading to increased intragallbladder pressure and pain. As in acute cholecystitis, biliary colic causes pain in the right upper quadrant. However, unlike acute cholecystitis, the pain is entirely visceral in origin, without true gallbladder wall inflammation. As the gallbladder relaxes, the stones often fall back from the cystic duct. As a result, the attack reaches a crescendo over a number of hours and then resolves completely.",
"   </p>",
"   <p>",
"    Most patients who develop acute cholecystitis have had previous attacks of biliary colic, which may further confuse the diagnosis or lead patients to delay seeking medical attention. The following features may help to distinguish an attack of biliary colic from acute cholecystitis. However, such patients usually require imaging studies to help establish the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain of biliary colic typically reaches a crescendo, and then resolves completely. Pain resolution occurs when the gallbladder relaxes, permitting stones to fall back from the cystic duct. An episode of right upper quadrant pain lasting for more than four to six hours should raise suspicion for acute cholecystitis.",
"     </li>",
"     <li>",
"      Patients with constitutional symptoms such as malaise or fever are more likely to have acute cholecystitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of other conditions can give rise to symptoms in the upper abdomen, which may be confused with biliary colic or acute cholecystitis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute pancreatitis.",
"     </li>",
"     <li>",
"      Appendicitis.",
"     </li>",
"     <li>",
"      Acute hepatitis.",
"     </li>",
"     <li>",
"      Peptic ulcer disease.",
"     </li>",
"     <li>",
"      Diseases of the right kidney.",
"     </li>",
"     <li>",
"      Right-sided pneumonia.",
"     </li>",
"     <li>",
"      Fitz-Hugh-Curtis syndrome (perihepatitis caused by gonococcal infection). Right upper quadrant pain with fever and even a possible positive Murphy's sign in patients at high risk for sexually transmitted diseases should raise this possibility. The HIDA scan is usually negative but pericholecystic fluid may be confused with acute cholecystitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65754 \" href=\"UTD.htm?8/38/8801\">",
"       image 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Subhepatic or intraabdominal abscess.",
"     </li>",
"     <li>",
"      Perforated viscus.",
"     </li>",
"     <li>",
"      Cardiac ischemia.",
"     </li>",
"     <li>",
"      Black widow spider envenomation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29208/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions can usually be differentiated by the clinical setting in which they occur and by obtaining the appropriate diagnostic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"       \"Patient information: Gallstones (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       \"Patient information: Gallstones (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cholecystitis refers to a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation and is usually related to gallstone disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute cholecystitis typically complain of abdominal pain, most commonly in the right upper quadrant or epigastrium. The pain may radiate to the right shoulder or back. Characteristically, acute cholecystitis pain is steady and severe. Associated complaints may include nausea, vomiting, and anorexia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute cholecystitis should be suspected when a patient presenting with the clinical manifestations outlined above is found to have gallstones on an imaging study. However, the mere presence of gallstones is not a sine qua non for acute cholecystitis, since asymptomatic cholelithiasis is a common condition in the general population. Thus, confirmation of the diagnosis must be based upon a combination of physical findings, laboratory studies, and imaging tests (",
"      <a class=\"graphic graphic_algorithm graphicRef50032 \" href=\"UTD.htm?30/12/30912\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute cholecystitis must be distinguished from the more benign condition of biliary colic, which presents with the same type of pain. Most patients who develop acute cholecystitis have had previous attacks of biliary colic, which may further confuse the diagnosis or lead patients to delay seeking medical attention. The following features may help to distinguish an attack of biliary colic from acute cholecystitis, though such patients usually require imaging studies to help establish the diagnosis (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The pain of biliary colic typically reaches a crescendo, and then resolves completely. Pain resolution occurs when the gallbladder relaxes, permitting stones to fall back from the cystic duct. An episode of right upper quadrant pain lasting for more than four to six hours should raise suspicion for acute cholecystitis.",
"     </li>",
"     <li>",
"      Patients with constitutional symptoms such as malaise or fever are more likely to have acute cholecystitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left untreated, symptoms of cholecystitis may abate within 7 to 10 days. However, complications can occur at alarmingly high rates, which is why urgent plans for treatment must be entertained. The most common complication is the development of gallbladder gangrene (up to 20 percent of cases) with subsequent perforation (2 percent of cases). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"       \"Treatment of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/1\">",
"      Barie PS, Fischer E. Acute acalculous cholecystitis. J Am Coll Surg 1995; 180:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/2\">",
"      Ziessman HA. Cholecystokinin cholescintigraphy: clinical indications and proper methodology. Radiol Clin North Am 2001; 39:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/3\">",
"      Kalloo AN, Kantsevoy SV. Gallstones and biliary disease. Prim Care 2001; 28:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/4\">",
"      Ahmed A, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician 2000; 61:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/5\">",
"      Nahrwold DL, Rose RC, Ward SP. Abnormalities in gallbladder morphology and function in patients with cholelithiasis. Ann Surg 1976; 184:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/6\">",
"      Park MS, Yu JS, Kim YH, et al. Acute cholecystitis: comparison of MR cholangiography and US. Radiology 1998; 209:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/7\">",
"      MORRIS CR, HOHF RP, IVY AC. An experimental study of the role of stasis in the etiology of cholecystitis. Surgery 1952; 32:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/8\">",
"      Roslyn JJ, DenBesten L, Thompson JE Jr, Silverman BF. Roles of lithogenic bile and cystic duct occlusion in the pathogenesis of acute cholecystitis. Am J Surg 1980; 140:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/9\">",
"      Kaminski DL. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterology 1989; 97:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/10\">",
"      Jiveg&aring;rd L, Thornell E, Svanvik J. Pathophysiology of acute obstructive cholecystitis: implications for non-operative management. Br J Surg 1987; 74:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/11\">",
"      Myers SI, Bartula L. Human cholecystitis is associated with increased gallbladder prostaglandin I2 and prostaglandin E2 synthesis. Hepatology 1992; 16:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/12\">",
"      Thornell E, Jansson R, Svanvik J. Indomethacin reduces raised intraluminal gallbladder pressure in acute cholecystitis. Acta Chir Scand 1985; 151:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/13\">",
"      Thornell E, Jansson R, Svanvik J. Indomethacin intravenously--a new way for effective relief of biliary pain: a double-blind study in man. Surgery 1981; 90:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/14\">",
"      Akriviadis EA, Hatzigavriel M, Kapnias D, et al. Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study. Gastroenterology 1997; 113:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/15\">",
"      Csendes A, Burdiles P, Maluenda F, et al. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg 1996; 131:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/16\">",
"      Barbara L, Sama C, Morselli Labate AM, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 1987; 7:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/17\">",
"      Kraag N, Thijs C, Knipschild P. Dyspepsia--how noisy are gallstones? A meta-analysis of epidemiologic studies of biliary pain, dyspeptic symptoms, and food intolerance. Scand J Gastroenterol 1995; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/18\">",
"      Singer AJ, McCracken G, Henry MC, et al. Correlation among clinical, laboratory, and hepatobiliary scanning findings in patients with suspected acute cholecystitis. Ann Emerg Med 1996; 28:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/19\">",
"      Adedeji OA, McAdam WA. Murphy's sign, acute cholecystitis and elderly people. J R Coll Surg Edinb 1996; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/20\">",
"      Reiss R, Nudelman I, Gutman C, Deutsch AA. Changing trends in surgery for acute cholecystitis. World J Surg 1990; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/21\">",
"      Roslyn JJ, Thompson JE Jr, Darvin H, DenBesten L. Risk factors for gallbladder perforation. Am J Gastroenterol 1987; 82:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/22\">",
"      Clavien PA, Richon J, Burgan S, Rohner A. Gallstone ileus. Br J Surg 1990; 77:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/23\">",
"      Lorenz RW, Steffen HM. Emphysematous cholecystitis: diagnostic problems and differential diagnosis of gallbladder gas accumulations. Hepatogastroenterology 1990; 37 Suppl 2:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/24\">",
"      Sarmiento RV. Emphysematous cholecystitis. Report of four cases and review of the literature. Arch Surg 1966; 93:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/25\">",
"      Mentzer RM Jr, Golden GT, Chandler JG, Horsley JS 3rd. A comparative appraisal of emphysematous cholecystitis. Am J Surg 1975; 129:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/26\">",
"      Garcia-Sancho Tellez L, Rodriguez-Montes JA, Fernandez de Lis S, Garcia-Sancho Martin L. Acute emphysematous cholecystitis. Report of twenty cases. Hepatogastroenterology 1999; 46:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/27\">",
"      Trowbridge RL, Rutkowski NK, Shojania KG. Does this patient have acute cholecystitis? JAMA 2003; 289:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/28\">",
"      Kurzweil SM, Shapiro MJ, Andrus CH, et al. Hyperbilirubinemia without common bile duct abnormalities and hyperamylasemia without pancreatitis in patients with gallbladder disease. Arch Surg 1994; 129:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/29\">",
"      Ralls PW, Colletti PM, Lapin SA, et al. Real-time sonography in suspected acute cholecystitis. Prospective evaluation of primary and secondary signs. Radiology 1985; 155:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/30\">",
"      Cooperberg PL, Burhenne HJ. Real-time ultrasonography. Diagnostic technique of choice in calculous gallbladder disease. N Engl J Med 1980; 302:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/31\">",
"      Shea JA, Berlin JA, Escarce JJ, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med 1994; 154:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/32\">",
"      Kalimi R, Gecelter GR, Caplin D, et al. Diagnosis of acute cholecystitis: sensitivity of sonography, cholescintigraphy, and combined sonography-cholescintigraphy. J Am Coll Surg 2001; 193:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/33\">",
"      Chatziioannou SN, Moore WH, Ford PV, Dhekne RD. Hepatobiliary scintigraphy is superior to abdominal ultrasonography in suspected acute cholecystitis. Surgery 2000; 127:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/34\">",
"      Kiewiet JJ, Leeuwenburgh MM, Bipat S, et al. A systematic review and meta-analysis of diagnostic performance of imaging in acute cholecystitis. Radiology 2012; 264:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/35\">",
"      Zakko SF, Srb S, Ramsby GR. Sensitivity of percutaneous endoscopy compared with ultrasonography in the detection of residue or mucosal lesions after topical gallbladder stone dissolution. Gastrointest Endosc 1995; 42:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/36\">",
"      Fink-Bennett D, Freitas JE, Ripley SD, Bree RL. The sensitivity of hepatobiliary imaging and real-time ultrasonography in the detection of acute cholecystitis. Arch Surg 1985; 120:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/37\">",
"      Kim EE, Moon TY, Delpassand ES, et al. Nuclear hepatobiliary imaging. Radiol Clin North Am 1993; 31:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/38\">",
"      Flancbaum L, Choban PS, Sinha R, Jonasson O. Morphine cholescintigraphy in the evaluation of hospitalized patients with suspected acute cholecystitis. Ann Surg 1994; 220:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/39\">",
"      Oates E, Selland DL, Chin CT, Achong DM. Gallbladder nonvisualization with pericholecystic rim sign: morphine-augmentation optimizes diagnosis of acute cholecystitis. J Nucl Med 1996; 37:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/40\">",
"      Paulson EK. Acute cholecystitis: CT findings. Semin Ultrasound CT MR 2000; 21:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/41\">",
"      Fidler J, Paulson EK, Layfield L. CT evaluation of acute cholecystitis: findings and usefulness in diagnosis. AJR Am J Roentgenol 1996; 166:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/42\">",
"      Barakos JA, Ralls PW, Lapin SA, et al. Cholelithiasis: evaluation with CT. Radiology 1987; 162:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/43\">",
"      Benarroch-Gampel J, Boyd CA, Sheffield KM, et al. Overuse of CT in patients with complicated gallstone disease. J Am Coll Surg 2011; 213:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29208/abstract/44\">",
"      Bush SP. Black widow spider envenomation mimicking cholecystitis. Am J Emerg Med 1999; 17:315.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 666 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-7C4F869326-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29208=[""].join("\n");
var outline_f28_33_29208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gangrene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Perforation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cholecystoenteric fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Emphysematous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cholescintigraphy (HIDA scan)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Morphine cholescintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Magnetic resonance cholangiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Oral cholecystography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/666|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/12/30912\" title=\"algorithm 1\">",
"      Diagnosis acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/666|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/62/35810\" title=\"diagnostic image 1\">",
"      Ultrasound acute cholecystitis gangrene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/26/32168\" title=\"diagnostic image 2\">",
"      CT of liver abscess in acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/16/38150\" title=\"diagnostic image 3\">",
"      CT scan peritoneal perforation of the gallbladder fundus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/37/1618\" title=\"diagnostic image 4\">",
"      Gallstone ileus on computed tomography of the abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/57/42899\" title=\"diagnostic image 5\">",
"      Emphysematous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/37/2642\" title=\"diagnostic image 6\">",
"      Ultrasound acute cholecystitis and Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/57/5015\" title=\"diagnostic image 7\">",
"      Acute cholecystitis with pericholecystic fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/52/9024\" title=\"diagnostic image 8\">",
"      Normal HIDA scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/13/27856\" title=\"diagnostic image 9\">",
"      Acute cholecystitis positive HIDA scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/5/5206\" title=\"diagnostic image 10\">",
"      MRI acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/55/13173\" title=\"diagnostic image 11\">",
"      CT scan acute calculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/63/10233\" title=\"diagnostic image 12\">",
"      CT scan and US acute calculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/38/8801\" title=\"diagnostic image 13\">",
"      Fitz-Hugh-Curtis syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/666|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/22/13679\" title=\"picture 1\">",
"      Percutaneous gallbladder endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26598?source=related_link\">",
"      Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29209="Clinical features of cerebral palsy";
var content_f28_33_29209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features of cerebral palsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Geoffrey Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29209/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/33/29209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) consists of a heterogeneous group of nonprogressive clinical syndromes that are characterized by motor and postural dysfunction. These conditions, which range in severity, are due to abnormalities of the developing brain resulting from a variety of causes. Although the disorder itself is not progressive, the appearance of neuropathologic lesions and their clinical expression may change over time as the brain matures.",
"   </p>",
"   <p>",
"    The clinical manifestations of CP are reviewed here. The epidemiology, etiology, diagnosis, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4104?source=see_link\">",
"     \"Diagnosis and classification of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link\">",
"     \"Management and prognosis of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerebral palsy (CP) syndromes are characterized by abnormalities of motor activity and posture. In affected patients, a voluntary movement that should be complex, coordinated, and varied is instead uncoordinated, stereotypic, and limited. Simple actions that are performed unconsciously by unaffected individuals require marked effort and concentration and often fail in patients with CP. In severely affected individuals, an attempted voluntary movement may evoke a primitive reflex, co-contraction of agonist and antagonist muscles, and mass movements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/1\">",
"     1",
"    </a>",
"    ]. For example, attempts at flexion may involve all segments of a limb, and extension of all the fingers may accompany extension of the wrist. Discrete movements, such as that of an individual finger, may be impossible.",
"   </p>",
"   <p>",
"    Classification of CP syndromes is based upon the type and distribution of motor abnormalities (",
"    <a class=\"graphic graphic_table graphicRef74533 \" href=\"UTD.htm?29/5/29787\">",
"     table 1",
"    </a>",
"    ). However, there may be substantial overlap among the clinical features. For example, patients with spastic syndromes may have involuntary abnormal movements, and those with dyskinetic and ataxic syndromes may have pyramidal signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spastic syndromes have variable expression. They may be symmetric or asymmetric, and may involve one or more extremities. These variations are important in identifying etiology, associated findings, and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with spastic CP have features of an upper motor neuron syndrome, which include positive and negative signs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A positive sign is an abnormality that leads to involuntarily increased muscle activity or movement patterns. A negative sign reflects insufficient muscle activity or insufficient control of muscle activity that interferes with function. These differ from signs of upper motor neuron syndrome with adult onset because the developing nervous system may respond differently to insults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive signs of spastic CP include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spastic hypertonia",
"     </li>",
"     <li>",
"      Hyperreflexia caused by hyperexcitability of the stretch reflex",
"     </li>",
"     <li>",
"      Extensor plantar responses",
"     </li>",
"     <li>",
"      Clonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spastic hypertonia is the velocity-dependent increased resistance that occurs in response to passive muscle stretch. In the classic form, described as clasp-knife, the maximum resistance occurs after a few degrees of passive movement of a joint, which then relaxes after continued effort by the examiner. More rapid movement of the joint increases the degree of resistance, and decreases its time of onset. Spastic hypertonia is increased by stress and during voluntary movement when co-contraction of agonist and antagonist muscles may occur. In the most severe form, the affected part is rigid in flexion or extension. It tends to decrease during sleep.",
"   </p>",
"   <p>",
"    Negative signs of spastic CP include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Slow effortful voluntary movements",
"     </li>",
"     <li>",
"      Impaired fine-motor function",
"     </li>",
"     <li>",
"      Difficulty in isolating individual movements",
"     </li>",
"     <li>",
"      Fatigability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Classification of the spastic CP syndromes depends upon the distribution of abnormal upper motor neuron signs. Spastic diplegia occurs when the lower limbs are more affected than the upper limbs. In quadriplegia, all limbs are affected; upper limbs may be equally or more involved than lower limbs. Involvement of one side of the body is termed hemiplegia. The suffix &ldquo;-paresis&rdquo; denotes weakness and &ldquo;-plegia&rdquo; means paralysis. However, these terms often are used interchangeably and do not necessarily imply a difference in severity. Mild dyskinetic signs (eg, involuntary movements) may occur in all the spastic syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Spastic diplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spastic diplegia affects both term and preterm infants. Spastic diplegia in preterm infants often is associated with periventricular leukomalacia (PVL), and the risk is greater with increasing prematurity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"     \"Periventricular leukomalacia\"",
"    </a>",
"    .) The lower limbs are affected predominantly. Patients with mild PVL may have relatively good hand function and fewer associated disabilities. In more severely affected patients, upper limb function also may be compromised, depending upon the degree of spasticity, presence of contractures, sensory loss, associated involuntary movements, and intelligence.",
"   </p>",
"   <p>",
"    Affected patients have variable degrees of flexion at the elbows and knees; and flexion, adduction, and internal rotation of the hips. They may have an equinovalgus or calcaneovarus deformity of the foot. Extension of the fingers, abduction of the thumb, extension of the wrist, and supination of the forearm may be limited. These features may be associated with poor grasp release and involuntary or associated movements.",
"   </p>",
"   <p>",
"    Atrophy below the waist occurs in many patients. Sensory disturbances of central nervous system origin, such as poor two-point discrimination and astereognosis, are common in all the spastic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/6\">",
"     6",
"    </a>",
"    ]. Vasomotor abnormalities also occur.",
"   </p>",
"   <p>",
"    More severe associated disabilities usually occur in asymmetric than in symmetric spastic diplegia. Some cases may be caused by PVL and associated unilateral hemorrhagic infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Spastic hemiplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spastic hemiplegia typically affects term infants of normal birth weight. Most cases in term infants result from maldevelopment, prenatal circulatory disturbances, or neonatal stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    .) Prenatal causes include hypercoagulable states, vasculopathies, abnormal development of blood vessels, and emboli secondary to disorders affecting the placenta or fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/11\">",
"     11",
"    </a>",
"    ]. Causes of strokes that occur during early infancy include sepsis, disseminated intravascular coagulation, venous sinus thrombosis, emboli, and congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Some cases are caused by periventricular atrophy or cerebral dysgenesis. Affected patients with nondiagnostic neuroimaging may have maldevelopment at a microscopic level [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/8,14\">",
"     8,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation of congenital spastic hemiplegia is variable. It is usually caused by a cortical lesion. Thus, the arm typically is more affected than the leg. The condition may be missed during the newborn period and become evident during a later examination. It may be detected when an infant's caregiver notices hand dominance, reduced movement, or abnormal posturing on one side. The disorder sometimes is detected after a seizure occurs.",
"   </p>",
"   <p>",
"    As the clinical features evolve, movement and tone on the affected side typically decrease before tone and tendon reflexes abnormally increase. The typical posture appears when the child is approximately two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/1\">",
"     1",
"    </a>",
"    ]. The arm is adducted at the shoulder and flexed at the elbow, the forearm is pronated, and the wrist and fingers are flexed with the hand closed. The hip is partially flexed and adducted, and the knee and ankle are flexed because of increased tone in the hamstring and plantar flexor muscles. The foot may remain in the equinovarus or calcaneovalgus position.",
"   </p>",
"   <p>",
"    In mildly affected patients, the postural abnormalities are more apparent during walking or running. However, unless severe intellectual disability is present, independent walking usually occurs at the appropriate age or is only slightly delayed.",
"   </p>",
"   <p>",
"    In spastic hemiplegia with a postnatal etiology, motor handicap usually is only mild or moderate. Athetotic posturing sometimes accompanies the spasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Associated disabilities, such as intellectual impairment, hemianopsia, and seizures, may be worse than in cases with prenatal or perinatal causes. Cognitive deficits tend to be worse in infants with seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insults before the child reaches five years of age are more likely to adversely affect IQ compared to later events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/18\">",
"     18",
"    </a>",
"    ]. This is because peak synaptic production and elimination occur prior to this period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. IQ, or the difference between performance and verbal IQ, is not affected by the side of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Verbal-performance discrepancy may be attributable to visuospatial impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. In general, language development is related to cognitive ability.",
"   </p>",
"   <p>",
"    Most children with spastic hemiplegia also have sensory deficits. These are correlated with poor growth of the affected side, although not with the severity of the motor deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Spastic quadriplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spastic quadriplegia is the most severe form of spastic CP. It usually affects term infants who are small for gestational age, consistent with a prenatal origin, such as cerebral dysgenesis or infection. Other cases result from perinatal or postnatal events or a combination of prenatal and perinatal causes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/23\">",
"     23",
"    </a>",
"    ]. This disorder also is seen in extremely low birth weight infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected infants typically are severely handicapped. In addition to spasticity, they may have dystonia and feeding and respiratory difficulties because of pseudobulbar palsy.",
"   </p>",
"   <p>",
"    The characteristics of this disorder were investigated in a population-based study of 96 affected children born in Sweden from 1959 to 1978 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. The etiology was considered prenatal (eg, microcephaly, CNS maldevelopment, intrauterine infection), perinatal (eg, cerebral hemorrhage), or postnatal (eg, CNS infection) in 50 to 55, 30, and 15 to 20 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/25\">",
"     25",
"    </a>",
"    ]. Among the prenatal and perinatal cases, 21 percent were small for gestational age. All the patients had severe spastic paresis of all limbs, resulting in profound motor disability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/23\">",
"     23",
"    </a>",
"    ]. All had severe intellectual disability, and none could speak. Seizures occurred in 94 percent. Hip subluxation, contractures, and scoliosis were present in 75, 73, and 72 percent, respectively, and 47 percent had severe visual impairment. Microcephaly was congenital or secondary in 13 and 68 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dyskinetic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyskinetic CP typically affects term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/26\">",
"     26",
"    </a>",
"    ]. In most cases, it results from severe, acute perinatal asphyxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    .) The disorder is associated with status marmoratus (lesions in the basal ganglia and thalamus with a marbled appearance) that may appear as high-intensity areas on T2-weighted MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Dyskinetic CP results from selective neuronal necrosis in the hippocampus, thalamus, basal ganglia, reticular formation, and Purkinje cells of the cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neonatal presentation includes encephalopathy characterized by lethargy, decreased spontaneous movement, hypotonia, and suppressed primitive reflexes. Multiple organs may be affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29623?source=see_link\">",
"     \"Systemic effects of perinatal asphyxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dyskinetic syndromes are characterized by the involuntary movements of athetosis, chorea, and dystonia. They are divided into two categories, according to the predominant type of abnormal movement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/30\">",
"     30",
"    </a>",
"    ]. One type is mainly athetoid, in which movements are athetoid, choreiform, or a combination of both. The second type is mainly dystonic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Athetosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athetosis consists of slow, smooth, writhing movements that involve distal muscles. There is dyssynergia (antagonistic action) of opposing muscle groups, such as flexion and extension or pronation and supination. Emotion, change in posture, or intended movement may accentuate or induce the abnormal movements. Athetosis is most apparent during reaching, as the fingers extend and abduct. Primitive reflexes often are retained. Oropharyngeal difficulties may result from facial grimacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea consists of rapid, irregular, unpredictable contractions of individual muscles or small muscle groups that involve the face, bulbar muscles, proximal extremities, and fingers and toes. Stress, excitement, or fever may exacerbate the chorea. In some cases, fever may result in ballismus, a form of severe, coarse chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second category of dyskinetic CP is characterized by dystonia, although tension and persistent neonatal reflex patterns often occur. Dystonia consists of repetitive, patterned, twisting, and sustained movements of the trunk and limbs that may be either slow or rapid. Affected patients usually are severely disabled in all four limbs, the trunk, and pharyngeal muscles.",
"   </p>",
"   <p>",
"    The presentation of dyskinetic CP is variable. The muscle tone typically is normal or hypotonic, especially in early childhood. Infants tend to have retention of primitive reflexes, involuntary grimacing, a tendency to drool, and delayed psychomotor development. The involuntary movements evolve with time and may not be apparent until the child is two to three years of age. Unlike spastic CP, contractures usually do not develop, unless they are positional.",
"   </p>",
"   <p>",
"    If hypertonus develops, it is the \"tension\" type. Tension is a sudden involuntary increase in tone that affects both flexor and extensor muscles. The limbs become stiff during attempted movement or with emotion. Tendon reflexes are normal or may be difficult to elicit. Clonus and extensor plantar responses are absent, although athetoid movements of the toes may be confusing. Tension may be reduced with relaxation or a change in posture.",
"   </p>",
"   <p>",
"    Patients often have more than one form of involuntary movement, and the types may overlap in some cases. The extent of dysarthria and motor and intellectual disability are variable. However, patients with the dystonic type tend to be more severely affected than those with the other dyskinetic syndromes, and also may have pyramidal signs and anarthria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ataxic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ataxia indicates an incoordination of cerebellar or sensory origin, ataxic CP represents a widespread disorder of motor function. Affected patients usually are born at term.",
"   </p>",
"   <p>",
"    The etiology of ataxic CP is heterogeneous. Most cases are caused by early prenatal events. Some cases have genetic causes. Autosomal recessive conditions include cerebellar hypoplasia, granule cell deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/32\">",
"     32",
"    </a>",
"    ], and Joubert syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/33\">",
"     33",
"    </a>",
"    ]. An autosomal dominant form of nonprogressive ataxia has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/34\">",
"     34",
"    </a>",
"    ]. Congenital hypoplasia of the cerebellum and pure ataxia occur rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of ataxic CP is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/35\">",
"     35",
"    </a>",
"    ]. Most patients have congenital hypotonia. Motor milestones and language skills typically are delayed. Ataxia usually improves with time. In general, associated disabilities are worse with increasing severity of motor impairment. Speech, which is related to intellectual ability, typically is slow, jerky, and explosive.",
"   </p>",
"   <p>",
"    The diagnosis of ataxic CP is made by exclusion, as all patients with CP have incoordination and disturbed posture. Other causes of weakness, spasticity, dystonia, or choreoathetosis should be ruled out. Ataxic CP also should be distinguished from progressive neurodegenerative disorders, which may present with some of the same features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atonic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atonic syndromes comprise another form of CP. Although first described in 1910, atonic CP often is absent from contemporary classifications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected infants usually are born at term with severe hypotonia. Many have cerebral dysgenesis, microcephaly, and profound intellectual disability. Development is extremely delayed, and affected children never stand or walk.",
"   </p>",
"   <p>",
"    Typical findings that characterize other CP syndromes are absent in this disorder. Tone often remains decreased for approximately 12 to 18 months and then becomes variable and paratonic (ie, with passive movement of a joint, resistance increases proportionally to the amount of pressure applied).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) often is accompanied by other disorders of cerebral function. Associated abnormalities may affect cognition, vision, hearing, language, cortical sensation, attention, vigilance, and behavior. Some children have epilepsy, and many have disturbed gastrointestinal function and growth. Dyspraxias and agnosias may interfere with skilled tasks, regardless of the severity of motor deficit. In a child with relatively mild CP, for example, disorders of higher cortical function may interfere with activities of daily living, such as dressing or managing buttons.",
"   </p>",
"   <p>",
"    A systematic review of published literature estimated the following frequencies of impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmental: Intellectual disability (50 percent); epilepsy (25 percent); behavior disorder (25 percent); sleep disorder (20 percent)",
"     </li>",
"     <li>",
"      Functional: Unable to walk (30 percent); unable to talk (25 percent); blind (10 percent); deaf (4 percent)",
"     </li>",
"     <li>",
"      Physical: Pain (75 percent); hip displacement (30 percent); bladder control problems (25 percent); drooling (20 percent); requiring tube feedings (7 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, children with more severe disabilities in one area also are more likely to have disabilities in other areas.",
"   </p>",
"   <p>",
"    Because of these risks, children with CP should undergo routine screening for intellectual, visual, auditory and speech impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/39\">",
"     39",
"    </a>",
"    ]. Abnormal screening results call for more detailed evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intellectual disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intellectual disability (mental retardation) occurs in approximately 52 percent of patients with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/39\">",
"     39",
"    </a>",
"    ]. The severity of intellectual disability often correlates with the extent of motor handicap, particularly in children with spastic CP. However, there is substantial variability in cognitive ability among affected individuals. Children with spastic quadriplegia are typically the most severely affected, while cognitive function usually is better with dyskinetic CP that is mainly athetoid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Language development in hemiplegia is related to cognitive ability rather than to the side of the lesion. As a group, children born at term do better with congenital than postnatally acquired hemiplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients without frank intellectual disability may still have learning disabilities that can affect educational potential [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H6#H6\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strategies for devising communication techniques, activities of daily living, and education are based on what a disabled child will understand. Psychometric assessments require time, repetition, and experience, as well as the use of a multidimensional approach that combines results from norm-, criterion-, and observation-referenced tests [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CP commonly have behavioral, emotional,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychiatric disorders. These may be related to the primary neurologic manifestations, including emotional lability, poor attention and vigilance, and obsessive-compulsive traits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/42\">",
"     42",
"    </a>",
"    ]. The secondary effects of dependency, frustration, and low self-esteem also may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy occurs in approximately 45 percent of patients with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/39,43\">",
"     39,43",
"    </a>",
"    ]. Seizures are most common in patients with spastic quadriplegia and acquired hemiplegia, and less common in mild symmetric spastic diplegia and CP that is mainly athetoid.",
"   </p>",
"   <p>",
"    The onset of seizures is typically during the first two years of life. Partial seizures with secondary generalization are the most common type. Infantile spasms occur in some infants, particularly those with microcephaly and spastic quadriplegic or atonic CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"     \"Clinical features and diagnosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intellectual disability is more common in CP patients with seizures than in those without seizures, and severe intellectual disability is more likely in those with multiple seizure types. Epilepsy can impose an additional handicap when it is difficult to control, or if anticonvulsant drug doses cause sedation that further impairs learning and socialization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Visual disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular and visual disorders are common in CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/39,46-51\">",
"     39,46-51",
"    </a>",
"    ]. As an example, in a study of 120 school age children with CP, the eye examination was abnormal in 80 percent, strabismus and clinically significant refractive errors each occurred in 50 percent, and amblyopia and visual field defects each occurred in 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low visual acuity may be due to cortical impairment. This was illustrated by a study of visual acuity in children with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/49\">",
"     49",
"    </a>",
"    ]. In 36 of 43 patients (84 percent) with low visual acuity not explained by ophthalmological examination, cerebral visual disturbance was considered a likely cause. Severe dyskinetic eye movements also can result in slow, variable, and highly inefficient visual function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/50,52\">",
"     50,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of ocular abnormalities after preterm birth is greater in children with than without CP. In one report, 558 children born before 32 weeks gestation (54 with CP) were examined at age two years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/53\">",
"     53",
"    </a>",
"    ]. Children with CP were significantly more likely to have cicatricial retinopathy of prematurity (15 versus 2 percent), cortical visual impairment (11 versus 0.2 percent), and strabismus (52 versus 8 percent). The rate of refractive error without other ocular abnormalities was similar in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Speech impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of speech and language, including aphasia and dysarthria, occur in about 40 to 50 percent of children with CP, and about 25 percent are nonverbal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/38,39,54\">",
"     38,39,54",
"    </a>",
"    ]. Abnormal function of oropharyngeal muscles and lack of coordination of breathing patterns contribute to speech disorders in some patients. Hearing impairment and intellectual disability may also play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hearing impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing impairment occurs in 10 to 20 percent of children with CP and about 5 percent are deaf [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. It is most common in those with very low birthweight or severe hypoxic-ischemic insults. In a series of 75 children with spastic CP, brainstem auditory evoked potentials were abnormal in 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/55\">",
"     55",
"    </a>",
"    ]. Sensorineural hearing loss is also a feature of CP caused by kernicterus, which also includes choreoathetosis. Early diagnosis and treatment of hearing loss in infants at risk may improve learning and language development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27865?source=see_link\">",
"     \"Screening the newborn for hearing loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology and etiology of cerebral palsy\", section on 'Kernicterus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Growth failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CP often have growth failure, which is primarily due to poor nutrition. In one report, 23 percent of 154 children ages 2 to 17 years with diplegic or hemiplegic CP had stunted growth [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/56\">",
"     56",
"    </a>",
"    ]. Linear growth was significantly reduced compared to healthy children. Approximately 30 percent of the patients were poorly nourished, as indicated by reduced body weight or diminished triceps skinfold measurement. Findings were similar in children with quadriplegic CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor nutritional status is caused by both inadequate intake and gastrointestinal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. More than 90 percent of patients may have clinically significant gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/60\">",
"     60",
"    </a>",
"    ]. These include swallowing disorders, chronic constipation, regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, chronic aspiration, and abdominal pain which, in one series, occurred in 60, 74, 32, 41, and 32 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/60\">",
"     60",
"    </a>",
"    ]. Gastroesophageal reflux also contributes to dental abnormalities, such as tooth erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-nutritional factors also affect growth in CP. In one report, growth was assessed on each side of the body in 20 children with hemiplegic CP who had normal stature and triceps skinfold measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/62\">",
"     62",
"    </a>",
"    ]. Measurements of length, breadth, and circumference were smaller on the affected side. Factors related to this differential growth are poorly understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary disease is a leading cause of death among patients with severe CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/63\">",
"     63",
"    </a>",
"    ]. In these patients, pulmonary disease typically is caused by recurrent aspiration due to gastroesophageal reflux and palatopharyngeal incoordination, or restrictive disease related to scoliosis. Gastrostomy feeding reduces aspiration during swallowing, but does not address aspiration of oral secretions, and may exacerbate gastroesophageal reflux. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link&amp;anchor=H29#H29\">",
"     \"Management and prognosis of cerebral palsy\", section on 'Survival'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link&amp;anchor=H24#H24\">",
"     \"Management and prognosis of cerebral palsy\", section on 'Feeding disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The respiratory problems may be exacerbated by poor coordination of respiratory muscles and chest deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Orthopedic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthopedic disorders common in children with CP include subluxation, dislocation, and progressive dysplasia of the hip, foot deformities, and scoliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. These may require orthotics, postural management,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical intervention. Adults with CP frequently report back, neck, and joint pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link&amp;anchor=H18#H18\">",
"     \"Management and prognosis of cerebral palsy\", section on 'Orthopedic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Osteopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors contribute to the development of osteopenia in patients with CP, including lack of mobility, feeding dysfunction, nutritional deficiency, and antiepileptic drug use, and can result in frequent fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. More than 70 percent of children with moderate to severe CP have reduced bone mineral density in the femur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/70\">",
"     70",
"    </a>",
"    ]. Osteopenia in children with CP appears to be related to a diminished rate of bone growth rather than bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with high doses of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39781?source=see_link\">",
"     pamidronate",
"    </a>",
"    for 12 months increased bone mineral density in a small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/72\">",
"     72",
"    </a>",
"    ]. Lower doses also appeared to be effective in an open label trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/73\">",
"     73",
"    </a>",
"    ]. A systematic review concluded that there is weak evidence that bisphosphonates reduce fracture rates, and there are some concerns that pamidronate and other bisphosphonates may make bones more brittle, and information about long-term risks of these drugs is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/74\">",
"     74",
"    </a>",
"    ]. Therefore, these drugs are generally reserved for pediatric patients with severe reductions in bone mineral density and pathological extremity fractures or vertebral compression. Weight-bearing regimens and supplementation of calcium and vitamin D have shown some merit, but the evidence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/69,74-77\">",
"     69,74-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Urinary disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty to 60 percent of children with CP have dysfunctional voiding symptoms, including enuresis, frequency, urgency, and stress incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. Symptomatic neurogenic bladder and incontinence is most common in individuals with bilateral CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/80\">",
"     80",
"    </a>",
"    ]. Continence often improves with age, but may relapse as the neurogenic bladder dysfunction progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Children with incontinence have difficulty sensing bladder fullness and tend to have lower bladder capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/82\">",
"     82",
"    </a>",
"    ]. The dysfunction is caused by urodynamic abnormalities, such as bladder hyperreflexia, detrusor sphincter dyssynergia, bladder hypertonia with leakage, and periodic relaxation of the distal sphincter during filling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/78\">",
"     78",
"    </a>",
"    ]. Other contributing factors can include reduced mobility and communication, poor cognition, low expectations of caregivers, and neurogenic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/83\">",
"     83",
"    </a>",
"    ]. Urinary infection and vesicoureteral reflux are not common in children with CP. Most children have normal storage pressures as measured by urodynamic testing, and the kidneys and bladder wall thickness are usually normal on ultrasonographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of patients with CP undergoing urodynamic testing, the following disorders were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Upper motor neuron lesion, with detrusor overactivity (86 percent)",
"     </li>",
"     <li>",
"      Mixed upper and lower motor neuron lesion (9 percent)",
"     </li>",
"     <li>",
"      Incomplete lower motor neuron lesion (2 percent)",
"     </li>",
"     <li>",
"      No urodynamic lesion (3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with milder forms of CP (ie, without significant limb spasticity) are also prone to detrusor overactivity, leading to urgency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    daytime and nighttime incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to CP patients with urinary incontinence is similar to that of patients without CP. The treatment of choice for detrusor overactivity is anticholinergic medication. However, this must be done judiciously, with careful monitoring of residual urine to prevent the development of retention (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41785?source=see_link&amp;anchor=H13887223#H13887223\">",
"     \"Management of bladder dysfunction in children\", section on 'Anticholinergic agents'",
"    </a>",
"    ). For children with CP who have features of a neurogenic bladder, management depends on whether the bladder is underactive or overactive, and may include anticholinergic medication, alterations of the toileting schedule or environment,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clean intermittent catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/80\">",
"     80",
"    </a>",
"    ]. The management of these patients is similar to that in patients with myelomeningocele. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=see_link\">",
"     \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NEUROLOGIC DETERIORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the primary lesion in cerebral palsy (CP) is static, neurologic signs may change or worsen with increasing age. In some cases, neurologic deterioration is due to cervical spondylotic myelopathy resulting from exaggerated neck flexion or extension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dystonia and other progressive movement disorders (eg, tremor, parkinsonism, myoclonus, chorea) may develop in patients with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. In one report of patients with static brain injury beginning at birth or during infancy, the onset of movement disorder occurred at an average of 26 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/87\">",
"     87",
"    </a>",
"    ]. The latency period was shorter in patients who sustained later insults. The mechanism is uncertain, although it may be related to continuing aberrant development of the nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/89\">",
"     89",
"    </a>",
"    ]. Dystonic reactions also may occur in brain-damaged children following ingestion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29209/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=see_link\">",
"       \"Patient information: Cerebral palsy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cerebral palsy (CP) syndromes are characterized by abnormalities of motor activity and posture. In affected patients, a voluntary movement that should be complex, coordinated, and varied is instead uncoordinated, stereotypic, and limited.",
"     </li>",
"     <li>",
"      Classification of CP syndromes is based upon the type of motor abnormalities (spastic, dyskinetic, or ataxic) and their distribution (",
"      <a class=\"graphic graphic_table graphicRef74533 \" href=\"UTD.htm?29/5/29787\">",
"       table 1",
"      </a>",
"      ). There may be substantial overlap among the clinical features.",
"     </li>",
"     <li>",
"      Spastic CP is an upper motor neuron syndrome, which includes spastic hypertonia, hyperreflexia, extensor plantar responses, and clonus. Affected patients also have slow effortful voluntary movements, impaired fine-motor function, difficulty in isolating individual movements, and fatigability. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spastic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyskinetic CP typically affects term infants and usually results from severe, acute perinatal asphyxia. The neonatal presentation includes encephalopathy characterized by lethargy, decreased spontaneous movement, hypotonia, and suppressed primitive reflexes. Affected individuals later develop involuntary movements of athetosis, chorea, and dystonia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dyskinetic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ataxic CP is characterized by ataxic movements and speech, usually associated with widespread disorders of motor function. It has multiple causes, including early prenatal events and genetic defects. The diagnosis of ataxic CP is made by exclusion, and other causes of weakness, spasticity, dystonia, or choreoathetosis should be ruled out, including progressive neurodegenerative disorders. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ataxic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CP often is accompanied by other disorders of cerebral function, including intellectual disability or specific learning disabilities, behavioral and emotional disorders, seizures and impaired vision and speech. Secondary consequences of CP may include poor growth and nutrition, orthopedic problems (eg, joint subluxations and dislocations and hip dysplasia), osteopenia, and urinary disorders. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Associated disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Crothers B, Paine S. The Natural History of Cerebral Palsy, Harvard University Press, Cambridge 1959.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/2\">",
"      Michaelis R, Edebol-Tysk K. Zerebralparesen. Paediatr Prax 1988; 36:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/3\">",
"      Burke D. Spasticity as an adaptation to pyramidal tract injury. Adv Neurol 1988; 47:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/4\">",
"      Landau WM. Clinical neuromythology II. Parables of palsy pills and PT pedagogy: a spastic dialectic. Neurology 1988; 38:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/5\">",
"      Myklebust BM. A review of myotatic reflexes and the development of motor control and gait in infants and children: a special communication. Phys Ther 1990; 70:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/6\">",
"      Lesn&yacute; I, Stehl&iacute;k A, Tom&aacute;sek J, et al. Sensory disorders in cerebral palsy: two-point discrimination. Dev Med Child Neurol 1993; 35:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/7\">",
"      Uvebrant P. Hemiplegic cerebral palsy. Aetiology and outcome. Acta Paediatr Scand Suppl 1988; 345:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/8\">",
"      Wiklund LM, Uvebrant P. Hemiplegic cerebral palsy: correlation between CT morphology and clinical findings. Dev Med Child Neurol 1991; 33:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/9\">",
"      Niemann G, Wakat JP, Kr&auml;geloh-Mann I, et al. Congenital hemiparesis and periventricular leukomalacia: pathogenetic aspects on magnetic resonance imaging. Dev Med Child Neurol 1994; 36:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/10\">",
"      Koelfen W, Freund M, Varnholt V. Neonatal stroke involving the middle cerebral artery in term infants: clinical presentation, EEG and imaging studies, and outcome. Dev Med Child Neurol 1995; 37:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/11\">",
"      Nelson KB. Prenatal origin of hemiparetic cerebral palsy: how often and why? Pediatrics 1991; 88:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/12\">",
"      Barmada MA, Moossy J, Shuman RM. Cerebral infarcts with arterial occlusion in neonates. Ann Neurol 1979; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/13\">",
"      Levy SR, Abroms IF, Marshall PC, Rosquete EE. Seizures and cerebral infarction in the full-term newborn. Ann Neurol 1985; 17:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/14\">",
"      Kuban KC, Leviton A. Cerebral palsy. N Engl J Med 1994; 330:188.",
"     </a>",
"    </li>",
"    <li>",
"     Freud S. Die Infantile Cerebrallahmung. In: Specielle Pathologie und Therapie, Nothnagel S (Ed), Holder, Vienna 1897. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/16\">",
"      Cazauvieilh JB. Recherches sur l'agenesie cerebrale et le paralysie congenitale. Arch Gen Med 1827; 14:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/17\">",
"      Vargha-Khadem F, Isaacs E, van der Werf S, et al. Development of intelligence and memory in children with hemiplegic cerebral palsy. The deleterious consequences of early seizures. Brain 1992; 115 Pt 1:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/18\">",
"      Goodman R, Yude C. IQ and its predictors in childhood hemiplegia. Dev Med Child Neurol 1996; 38:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/19\">",
"      Huttenlocher PR, de Courten C, Garey LJ, Van der Loos H. Synaptogenesis in human visual cortex--evidence for synapse elimination during normal development. Neurosci Lett 1982; 33:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/20\">",
"      Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res 1979; 163:195.",
"     </a>",
"    </li>",
"    <li>",
"     Teuber HL. Recovery of function after brain injury in man. In: Outcome of Severe Damage to the Central Nervous System (Ciba Foundation Symposium 34), Porter R, Fizsimmons DW (Eds), Elsevier, Amsterdam 1975. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/22\">",
"      Cooper J, Majnemer A, Rosenblatt B, Birnbaum R. The determination of sensory deficits in children with hemiplegic cerebral palsy. J Child Neurol 1995; 10:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/23\">",
"      Edebol-Tysk K. Epidemiology of spastic tetraplegic cerebral palsy in Sweden. I. Impairments and disabilities. Neuropediatrics 1989; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/24\">",
"      Ferrara TB, Hoekstra RE, Gaziano E, et al. Changing outcome of extremely premature infants (less than or equal to 26 weeks' gestation and less than or equal to 750 gm): survival and follow-up at a tertiary center. Am J Obstet Gynecol 1989; 161:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/25\">",
"      Edebol-Tysk K, Hagberg B, Hagberg G. Epidemiology of spastic tetraplegic cerebral palsy in Sweden. II. Prevalence, birth data and origin. Neuropediatrics 1989; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/26\">",
"      Foley J. Dyskinetic and dystonic cerebral palsy and birth. Acta Paediatr 1992; 81:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/27\">",
"      Yokochi K, Aiba K, Kodama M, Fujimoto S. Magnetic resonance imaging in athetotic cerebral palsied children. Acta Paediatr Scand 1991; 80:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/28\">",
"      Menkes JH, Curran J. Clinical and MR correlates in children with extrapyramidal cerebral palsy. AJNR Am J Neuroradiol 1994; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/29\">",
"      Robertson CM, Finer NN. Long-term follow-up of term neonates with perinatal asphyxia. Clin Perinatol 1993; 20:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/30\">",
"      Hagberg B, Hagberg G, Olow I. The changing panorama of cerebral palsy in Sweden 1954-1970. I. Analysis of the general changes. Acta Paediatr Scand 1975; 64:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/31\">",
"      Harbord MG, Kobayashi JS. Fever producing ballismus in patients with choreoathetosis. J Child Neurol 1991; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/32\">",
"      Mathews KD, Afifi AK, Hanson JW. Autosomal recessive cerebellar hypoplasia. J Child Neurol 1989; 4:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/33\">",
"      Joubert M, Eisenring JJ, Robb JP, Andermann F. Familial agenesis of the cerebellar vermis. A syndrome of episodic hyperpnea, abnormal eye movements, ataxia, and retardation. Neurology 1969; 19:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/34\">",
"      Kornberg AJ, Shield LK. An extended phenotype of an early-onset inherited nonprogressive cerebellar ataxia syndrome. J Child Neurol 1991; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/35\">",
"      Miller G, Cala LA. Ataxic cerebral palsy--clinico-radiologic correlations. Neuropediatrics 1989; 20:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/36\">",
"      YANNET H, HORTON F. Hypotonic cerebral palsy in mental defectives. Pediatrics 1952; 9:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/37\">",
"      Foerster O. Der atonisch-astatische typus der infantilen cerebrallahmung. Eur J Clin Invest 1910; 98:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/38\">",
"      Novak I, Hines M, Goldsmith S, Barclay R. Clinical prognostic messages from a systematic review on cerebral palsy. Pediatrics 2012; 130:e1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/39\">",
"      Ashwal S, Russman BS, Blasco PA, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004; 62:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/40\">",
"      Beckung E, Hagberg G. Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol 2002; 44:309.",
"     </a>",
"    </li>",
"    <li>",
"     Bagnato SJ, Campbell TF. Comprehensive neurodevelopmental evaluation of children with brain insults. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ranier JC (Eds), Raven, New York 1992. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/42\">",
"      Hurley AD, Sorrier R. Psychiatric aspects of cerebral palsy. Psychiatr Ment Retard Rev 1987; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/43\">",
"      Aksu F. Nature and prognosis of seizures in patients with cerebral palsy. Dev Med Child Neurol 1990; 32:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/44\">",
"      Aicardi J. Epilepsy in brain-injured children. Dev Med Child Neurol 1990; 32:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/45\">",
"      Hadjipanayis A, Hadjichristodoulou C, Youroukos S. Epilepsy in patients with cerebral palsy. Dev Med Child Neurol 1997; 39:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/46\">",
"      Black P. Visual disorders associated with cerebral palsy. Br J Ophthalmol 1982; 66:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/47\">",
"      Jan JE, Groenveld M, Sykanda AM, Hoyt CS. Behavioural characteristics of children with permanent cortical visual impairment. Dev Med Child Neurol 1987; 29:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/48\">",
"      Thurston SE, Leigh RJ, Crawford T, et al. Two distinct deficits of visual tracking caused by unilateral lesions of cerebral cortex in humans. Ann Neurol 1988; 23:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/49\">",
"      Schenk-Rootlieb AJ, van Nieuwenhuizen O, van der Graaf Y, et al. The prevalence of cerebral visual disturbance in children with cerebral palsy. Dev Med Child Neurol 1992; 34:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/50\">",
"      Buckley E, Seaber JH. Dyskinetic strabismus as a sign of cerebral palsy. Am J Ophthalmol 1981; 91:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/51\">",
"      Katayama M, Tamas LB. Saccadic eye-movements of children with cerebral palsy. Dev Med Child Neurol 1987; 29:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/52\">",
"      Jan JE, Lyons CJ, Heaven RK, Matsuba C. Visual impairment due to a dyskinetic eye movement disorder in children with dyskinetic cerebral palsy. Dev Med Child Neurol 2001; 43:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/53\">",
"      Pennefather PM, Tin W. Ocular abnormalities associated with cerebral palsy after preterm birth. Eye (Lond) 2000; 14 ( Pt 1):78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/54\">",
"      Nordberg A, Miniscalco C, Lohmander A, Himmelmann K. Speech problems affect more than one in two children with cerebral palsy: Swedish population-based study. Acta Paediatr 2013; 102:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/55\">",
"      Zafeiriou DI, Andreou A, Karasavidou K. Utility of brainstem auditory evoked potentials in children with spastic cerebral palsy. Acta Paediatr 2000; 89:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/56\">",
"      Stallings VA, Charney EB, Davies JC, Cronk CE. Nutritional status and growth of children with diplegic or hemiplegic cerebral palsy. Dev Med Child Neurol 1993; 35:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/57\">",
"      Stallings VA, Charney EB, Davies JC, Cronk CE. Nutrition-related growth failure of children with quadriplegic cerebral palsy. Dev Med Child Neurol 1993; 35:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/58\">",
"      Sondheimer JM, Morris BA. Gastroesophageal reflux among severely retarded children. J Pediatr 1979; 94:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/59\">",
"      Stevenson RD, Hayes RP, Cater LV, Blackman JA. Clinical correlates of linear growth in children with cerebral palsy. Dev Med Child Neurol 1994; 36:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/60\">",
"      Del Giudice E, Staiano A, Capano G, et al. Gastrointestinal manifestations in children with cerebral palsy. Brain Dev 1999; 21:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/61\">",
"      Shaw L, Weatherill S, Smith A. Tooth wear in children: an investigation of etiological factors in children with cerebral palsy and gastroesophageal reflux. ASDC J Dent Child 1998; 65:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/62\">",
"      Stevenson RD, Roberts CD, Vogtle L. The effects of non-nutritional factors on growth in cerebral palsy. Dev Med Child Neurol 1995; 37:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/63\">",
"      Reddihough DS, Baikie G, Walstab JE. Cerebral palsy in Victoria, Australia: mortality and causes of death. J Paediatr Child Health 2001; 37:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/64\">",
"      Flynn JM, Miller F. Management of hip disorders in patients with cerebral palsy. J Am Acad Orthop Surg 2002; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/65\">",
"      McCarthy JJ, D'Andrea LP, Betz RR, Clements DH. Scoliosis in the child with cerebral palsy. J Am Acad Orthop Surg 2006; 14:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/66\">",
"      Murphy KP, Molnar GE, Lankasky K. Medical and functional status of adults with cerebral palsy. Dev Med Child Neurol 1995; 37:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/67\">",
"      Chad KE, McKay HA, Zello GA, et al. Body composition in nutritionally adequate ambulatory and non-ambulatory children with cerebral palsy and a healthy reference group. Dev Med Child Neurol 2000; 42:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/68\">",
"      Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002; 110:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/69\">",
"      Cohen M, Lahat E, Bistritzer T, et al. Evidence-based review of bone strength in children and youth with cerebral palsy. J Child Neurol 2009; 24:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/70\">",
"      Mergler S, Evenhuis HM, Boot AM, et al. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Dev Med Child Neurol 2009; 51:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/71\">",
"      Henderson RC, Kairalla JA, Barrington JW, et al. Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy. J Pediatr 2005; 146:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/72\">",
"      Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/73\">",
"      Plotkin H, Coughlin S, Kreikemeier R, et al. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol 2006; 48:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/74\">",
"      Fehlings D, Switzer L, Agarwal P, et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol 2012; 54:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/75\">",
"      Caulton JM, Ward KA, Alsop CW, et al. A randomised controlled trial of standing programme on bone mineral density in non-ambulant children with cerebral palsy. Arch Dis Child 2004; 89:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/76\">",
"      Jekovec-Vrhovsek M, Kocijancic A, Prezelj J. Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000; 42:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/77\">",
"      Hough JP, Boyd RN, Keating JL. Systematic review of interventions for low bone mineral density in children with cerebral palsy. Pediatrics 2010; 125:e670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/78\">",
"      Decter RM, Bauer SB, Khoshbin S, et al. Urodynamic assessment of children with cerebral palsy. J Urol 1987; 138:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/79\">",
"      Silva JA, Gonsalves Mde C, Saverio AP, et al. Lower urinary tract dysfunction and ultrasound assessment of bladder wall thickness in children with cerebral palsy. Urology 2010; 76:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/80\">",
"      Murphy KP, Boutin SA, Ide KR. Cerebral palsy, neurogenic bladder, and outcomes of lifetime care. Dev Med Child Neurol 2012; 54:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/81\">",
"      Roijen LE, Postema K, Limbeek VJ, Kuppevelt VH. Development of bladder control in children and adolescents with cerebral palsy. Dev Med Child Neurol 2001; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/82\">",
"      Richardson I, Palmer LS. Clinical and urodynamic spectrum of bladder function in cerebral palsy. J Urol 2009; 182:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/83\">",
"      Borzyskowski M. Cerebral palsy and the bladder. Dev Med Child Neurol 1989; 31:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/84\">",
"      Bauer SB. Neurogenic bladder: etiology and assessment. Pediatr Nephrol 2008; 23:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/85\">",
"      Reese ME, Msall ME, Owen S, et al. Acquired cervical spine impairment in young adults with cerebral palsy. Dev Med Child Neurol 1991; 33:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/86\">",
"      Fletcher NA, Marsden CD. Dyskinetic cerebral palsy: a clinical and genetic study. Dev Med Child Neurol 1996; 38:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/87\">",
"      Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology 1996; 46:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/88\">",
"      Burke RE, Fahn S, Gold AP. Delayed-onset dystonia in patients with \"static\" encephalopathy. J Neurol Neurosurg Psychiatry 1980; 43:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/89\">",
"      Saint Hilaire MH, Burke RE, Bressman SB, et al. Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology 1991; 41:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/90\">",
"      Crosley CJ, Swender PT. Dystonia associated with carbamazepine administration: experience in brain-damaged children. Pediatrics 1979; 63:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29209/abstract/91\">",
"      Chalhub EG, Devivo DC, Volpe JJ. Phenytoin-induced dystonia and choreoathetosis in two retarded epileptic children. Neurology 1976; 26:494.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6167 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29209=[""].join("\n");
var outline_f28_33_29209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Spastic diplegia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Spastic hemiplegia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Spastic quadriplegia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dyskinetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Athetosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chorea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ataxic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atonic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intellectual disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Visual disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Speech impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hearing impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Growth failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Orthopedic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Osteopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Urinary disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NEUROLOGIC DETERIORATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6167\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6167|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/5/29787\" title=\"table 1\">",
"      Cerebral palsy syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4104?source=related_link\">",
"      Diagnosis and classification of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41785?source=related_link\">",
"      Management of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=related_link\">",
"      Patient information: Cerebral palsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27865?source=related_link\">",
"      Screening the newborn for hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29623?source=related_link\">",
"      Systemic effects of perinatal asphyxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=related_link\">",
"      Urinary tract complications of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29210="Antibiotic studies for the treatment of community-acquired pneumonia in adults";
var content_f28_33_29210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29210/contributors\">",
"     Thomas M File, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29210/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/33/29210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/33/29210/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/33/29210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAP can be caused by a variety of pathogens, with bacteria being the most common identifiable cause (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"UTD.htm?39/50/40751\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"UTD.htm?8/18/8495\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54365 \" href=\"UTD.htm?38/29/39390\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Antibiotic therapy is typically begun on an empiric basis since the causative organism is not identified in an appreciable proportion of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The choice of initial therapy is complicated by the emergence of antibiotic resistance among Streptococcus pneumoniae, the single most common bacterium responsible for CAP.",
"   </p>",
"   <p>",
"    The evidence for efficacy of different antibiotic medications in the empiric treatment of CAP and issues related to drug resistance will be reviewed here. A variety of other important issues related to CAP are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment recommendations for CAP in outpatients (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients requiring hospitalization (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The epidemiology and microbiology of CAP (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The diagnostic approach to patients with CAP (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      How one makes the decision to admit patients with CAP to the hospital (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPARISON OF SPECIFIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotic classes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional therapy for community-acquired pneumonia (CAP) has included beta-lactam (penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , and cephalosporins), macrolide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) antibiotics. Newer drugs in these categories, as well as new classes of drugs, including fluoroquinolones and ketolides, have added to the choice of agents.",
"   </p>",
"   <p>",
"    The superiority of one medication, or combination of medications, over another depends on the likelihood that a given pathogen is present (all regimens should cover pneumococcus, the most likely pathogen), the severity of the illness, antibiotic susceptibilities of pathogens in the community, and possible immunomodulatory effects of combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Quality of studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many studies have compared different antibiotic regimens, problems in interpreting the results arise from multiple issues in study design:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reports often compare new agents to antibiotics that are not considered a standard regimen for CAP (eg, penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies commonly involve small numbers of patients (eg, some with &le;50 patients per treatment group) and may not have had sufficient power to detect significant differences between treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/4,6\">",
"       4,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many studies are open-label trials.",
"     </li>",
"     <li>",
"      The definition of CAP is not uniform, including studies that do not require chest radiograph (CXR) confirmation of an infiltrate, and studies that include patients with bronchitis.",
"     </li>",
"     <li>",
"      Some studies involve both children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many studies lack consistent study design, such as stratification by severity of illness, selection of appropriate noninferiority margins, microbiologic confirmation of pathogens, appropriate clinical trial outcomes, and evaluation of safety issues [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical data are limited on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for CAP in the era of drug resistance. One prospective, non-blinded study, found that IV doxycycline was as efficacious as other regimens chosen to treat patients with CAP admitted to a community hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/9\">",
"     9",
"    </a>",
"    ]. However, only 43 evaluable patients were treated with doxycycline (44 with other routinely used regimens), and of these only 8 patients had documented infection due to S. pneumoniae; no patients had drug-resistant infection.",
"   </p>",
"   <p>",
"    A randomized trial of patients hospitalized for CAP compared IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/10\">",
"     10",
"    </a>",
"    ]. This study was also small with 30 and 35 patients in the levofloxacin and doxycycline arms, respectively. The mean Pneumonia Severity Index (PSI) was low in each group (class II), and fewer than 15 percent of patients had a positive sputum culture. The clinical response was similar with each group (one failure in the doxycycline arm and two failures in the levofloxacin arm); however, length of stay was shorter and the total antibiotic cost was less in the doxycycline arm.",
"   </p>",
"   <p>",
"    A retrospective study of empiric therapy for CAP evaluated outcomes in 858 patients who received a beta-lactam plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    versus a beta-lactam plus a macrolide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/11\">",
"     11",
"    </a>",
"    ]. Although patients in the two groups had similar PSI scores at the time of admission, a smaller proportion of patients who received doxycycline required invasive respiratory or vasopressor support than patients who received a macrolide. In addition, those who received doxycycline had a shorter time to clinical stability and a shorter inpatient length of stay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fluoroquinolones versus beta-lactams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large randomized treatment trials of CAP have compared fluoroquinolone therapy to treatment with beta-lactams with or without a macrolide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. In each study, clinical response was equivalent or superior in patients in the fluoroquinolone treatment group.",
"   </p>",
"   <p>",
"    In a meta-analysis that included 23 randomized trials, respiratory fluoroquinolones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    ) were more likely to result in treatment success than the combination of a beta-lactam plus a macrolide for the treatment of CAP that was mostly mild to moderate in severity (odds ratio, OR 1.39, 95% CI 1.02-1.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/19\">",
"     19",
"    </a>",
"    ]. However, fluoroquinolones were more effective only in open-labeled trials, but not in randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Levofloxacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, randomized, multicenter trial of 599 adults with CAP who could be treated as outpatients or in the hospital compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg intravenous or orally daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 to 2 g intravenous once or twice daily)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (500 mg orally twice daily) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/12\">",
"     12",
"    </a>",
"    ]. Clinical success at five to seven days after treatment was superior with levofloxacin (96 percent) compared with either cephalosporin arm (90 percent).",
"   </p>",
"   <p>",
"    Another randomized, multicenter trial of 619 hospitalized patients with CAP compared the efficacy of higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (4 g once daily), and found equivalent clinical responses two to five days following therapy (87 versus 86 percent cure or improvement) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two studies evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    in the treatment of more seriously ill patients with CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one study, 269 hospitalized patients were randomly assigned to levofloxacin (500 mg intravenous daily followed by oral administration) or a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 to 2 g intravenous or intramuscular daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 to 1000 mg intravenous every six hours) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (875 mg orally twice daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg orally twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/20\">",
"     20",
"    </a>",
"    ]. Equivalent clinical responses were observed in both treatment groups (89.5 compared to 83.1 percent treated with levofloxacin and combination therapy, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Moxifloxacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective randomized trial of 628 adults hospitalized with CAP compared treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (sequential intravenous then oral dosing at 400 mg once daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (sequential intravenous then oral) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (intravenous or oral) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/14\">",
"     14",
"    </a>",
"    ]. Higher clinical and bacteriological success rates were seen in patients in the moxifloxacin treatment group (93 versus 85 and 94 versus 82 percent for clinical and bacteriological success rates, respectively). In addition, use of moxifloxacin compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate (with or without clarithromycin) led to a more rapid resolution of fever, allowing 50 percent of patients in the moxifloxacin group to switch to oral therapy by day three.",
"   </p>",
"   <p>",
"    Sequential intravenous and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg once daily) was compared to a combination regimen of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily) plus sequential intravenous and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg twice daily) in a prospective, randomized, double-blind noninferiority trial of 733 patients with a PSI score of three to five who required hospitalization (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/42/44705?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/22\">",
"     22",
"    </a>",
"    ]. The overall clinical cure rates were 87 percent for moxifloxacin and 90 percent for the ceftriaxone plus levofloxacin regimen. The moxifloxacin regimen was considered to be noninferior to the comparator regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gemifloxacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, open label, multicenter study of 345 patients hospitalized with CAP compared treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    (320 mg daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g intravenous daily for one to seven days) followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (500 mg twice daily) with or without a macrolide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no difference in clinical response between the groups, demonstrating the utility of the highly bioavailable newer fluoroquinolones as oral agents. A follow-up study found a cost benefit of gemifloxacin compared with ceftriaxone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fluoroquinolones versus macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones have also been compared to macrolide monotherapy. Many of these studies were performed with fluoroquinolones that are no longer available, such as grepafloxacin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, a randomized, double-blind trial comparing extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    in CAP demonstrated comparable clinical and bacteriologic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies that have compared fluoroquinolones to beta-lactams with or without a macrolide are discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Fluoroquinolones versus beta-lactams'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fluoroquinolone versus fluoroquinolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, double-blind, trial of CAP in over 350 hospitalized patients compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg intravenous to oral) to trovafloxacin (200 mg intravenous to oral) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg intravenous to oral) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/27\">",
"     27",
"    </a>",
"    ]. Clinical response rates were the same for moxifloxacin and",
"    <span class=\"nowrap\">",
"     trovafloxacin/levofloxacin",
"    </span>",
"    (88 and 89 percent, respectively, in the valid for efficacy population).",
"   </p>",
"   <p>",
"    A subsequent prospective, double-blind trial of CAP in 281 hospitalized, elderly patients (age &ge;65 years) randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg",
"    <span class=\"nowrap\">",
"     intravenous/oral",
"    </span>",
"    daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg",
"    <span class=\"nowrap\">",
"     intravenous/oral",
"    </span>",
"    daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/28\">",
"     28",
"    </a>",
"    ]. Cure rates were similar for the clinically evaluable population (92.9 and 90.0 percent for moxifloxacin and levofloxacin, respectively). However, patients treated with moxifloxacin therapy had a significantly faster clinical recovery time than those treated with levofloxacin (98 compared to 90 percent resolution of fever at three to five days in the moxifloxacin and levofloxacin groups, respectively). There was no statistically significant difference between the treatment groups in drug-related adverse events.",
"   </p>",
"   <p>",
"    A second report from this same trial, specifically addressed the cardiac safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    in these patients since the fluoroquinolones are known to cause prolongation of the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/29\">",
"     29",
"    </a>",
"    ]. The primary endpoint was ventricular arrhythmia events in Holter monitoring, which was equivalent in both groups (8.3 and 5.1 percent for moxifloxacin-treated and levofloxacin-treated patients, respectively). One moxifloxacin treated patient had sustained monomorphic ventricular tachycardia (&gt;30 seconds), and one levofloxacin treated patient had torsade de pointes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H30#H30\">",
"     \"Fluoroquinolones\", section on 'QT interval prolongation and arrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Macrolides versus other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous trials have shown that macrolides are effective as monotherapy in outpatients with pneumonia. However, most patients had mild infections, and these studies were performed at a time when macrolide-resistant S. pneumoniae was less prevalent than it is currently (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Macrolide resistance'",
"    </a>",
"    below). A 2001 meta-analysis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    compared to other drugs for the treatment of CAP, identified 18 studies in the 1990s of variable quality; the comparator drug was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    in six,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    in three, and roxithromycin in two [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/7\">",
"     7",
"    </a>",
"    ]. Azithromycin generally showed comparable efficacy.",
"   </p>",
"   <p>",
"    An open-label, randomized trial published after the meta-analysis compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (intravenous, followed by oral) in 202 patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    in 96 and 105 patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/30\">",
"     30",
"    </a>",
"    ]. The regimens showed equal efficacy in these hospitalized patients, with a significantly shorter mean duration of parenteral and total therapy with azithromycin.",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of five randomized trials and 18 observational studies that included more than 137,000 hospitalized patients with CAP found that macrolide-based regimens were associated with a statistically significant mortality reduction compared with non-macrolide-based regimens (3.7 versus 6.5 percent; RR 0.78, 95% CI 0.64-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/31\">",
"     31",
"    </a>",
"    ]. However, there was no mortality benefit when the analysis was restricted to randomized trials (4.6 versus 4.1 percent; RR 1.13, 95% CI 0.65-1.98) or to patients treated with guideline-concordant antibiotics (5.3 percent for a macrolide-beta-lactam combination versus 5.8 percent for a respiratory fluoroquinolone, RR 1.17, 95% CI 0.91-1.50).",
"   </p>",
"   <p>",
"    A shorter duration of therapy could be an advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    therapy. One trial found a comparable clinical outcome with a three-day course of azithromycin (500 mg orally daily) to 10 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (250 mg orally twice daily) in 203 patients with mild to moderate CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/32\">",
"     32",
"    </a>",
"    ]. If larger studies document similar efficacy, this shorter regimen should improve patient compliance and is cost-effective. Other smaller studies have found comparable outcomes with a three-day course of azithromycin compared to other regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An oral formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (administered as microspheres dissolved in water) is available as a single dose, 2 g regimen for mild to moderate CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/36\">",
"     36",
"    </a>",
"    ]. Two randomized, controlled trials found similar clinical cure rates (range 90 to 95 percent) with single dose azithromycin (2 g orally) compared to seven days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (1 g extended release orally daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg orally daily) in patients with mild to moderate CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Adverse event rates were similar in the clarithromycin-comparative trial; but in the levofloxacin comparative study, there were more drug-related events (mostly mild or moderate in nature) in the azithromycin arm as compared to the levofloxacin arm (19.9 versus 12.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The macrolides have been associated with prolongation of the QT interval. In a large database analysis of adults aged 30 to 74 years, patients receiving a five-day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    had an increased risk of cardiovascular death compared with those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or no antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk of cardiovascular death in patients receiving azithromycin was highest among those with elevated cardiovascular risk scores. This study suggests that there is a small but significant increase in the risk of cardiovascular death among patients currently receiving azithromycin, compared with amoxicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or no drug, and that the risk was greatest in patients with cardiovascular risk factors. The majority of patients for whom the indication was known were receiving azithromycin for an upper respiratory tract infection. This study is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38757748\">",
"    <span class=\"h2\">",
"     Ceftaroline versus ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    is a broad-spectrum cephalosporin that has bactericidal activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and S. pneumoniae, as well as gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. It lacks activity against Pseudomonas aeruginosa. In two randomized, double-blind trials (FOCUS 1 and FOCUS 2) that compared ceftaroline (600 mg IV every 12 hours) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g IV every 24 hours) for five to seven days in patients hospitalized with CAP (but not admitted to an intensive care unit), ceftaroline was noninferior to ceftriaxone and had a safety profile that was similar to ceftriaxone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In the modified intention-to-treat analysis, the clinical cure rate was 83 percent for patients receiving ceftaroline compared with those receiving ceftriaxone (83 versus 77 percent; 95% CI 1.4-10.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/44\">",
"     44",
"    </a>",
"    ]. A possible explanation for this difference is the greater affinity of ceftaroline for S. pneumoniae penicillin-binding proteins (PBP), especially PBP 2X, which is the primary determinant of beta-lactam resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Daptomycin versus ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized, double-blind trials were performed to compare intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily) for 5 to 14 days for the treatment of CAP in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/46\">",
"     46",
"    </a>",
"    ]. Of the clinically evaluable patients, 369 received daptomycin and 371 received ceftriaxone;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    was added when gram-negative infection was suspected. The cure rate was significantly lower with daptomycin compared to ceftriaxone (79 versus 88 percent). A possible explanation is that daptomycin is inactivated by surfactant in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A post hoc analysis revealed that, among those who received up to 24 hours of prior effective therapy, cure rates were similar among the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    -treated patients (91 versus 88 percent). This observation suggests that as little as 24 hours of effective therapy may impact outcomes. Thus, patients who have already received potentially effective therapy for 24 hours should be excluded from prospective trials of the treatment of CAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tigecycline versus other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two phase 3 randomized trials were designed to test whether intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    was equivalent to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    in patients hospitalized with CAP, the majority of whom had a PSI score of II or III (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/42/44705?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/48\">",
"     48",
"    </a>",
"    ]. In one of the trials, patients in either arm could be switched to oral levofloxacin after at least three days of intravenous therapy in patients who demonstrated clinical improvement. In an intention-to-treat analysis that combined the results of the two trials, the cure rate with tigecycline was similar to levofloxacin (81 versus 80 percent). However, tigecycline was associated with more nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link&amp;anchor=H3#H3\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\", section on 'Pneumonia Severity Index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In September 2010, the United States Food and Drug Administration issued a safety announcement regarding an increased mortality risk associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    compared with that of other drugs that was observed in a pooled analysis of 13 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/49\">",
"     49",
"    </a>",
"    ]. The increased risk was seen most clearly in patients treated for hospital-acquired pneumonia, particularly ventilator-associated pneumonia; however, there was no difference in mortality rate for CAP (mortality of 2.8 versus 2.6 percent, 95% CI 2.0-2.4). A 2012 meta-analysis of 10 published and 3 unpublished randomized noninferiority trials also found that tigecycline was associated with an absolute mortality increase of 0.7 percent (95% CI 0.1-1.2 percent) compared with other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, tigecycline was associated with an absolute increase in noncure rate of 2.9 percent (95% CI 0.6-5.2 percent) among patients who received tigecycline. These effects were not isolated to a specific type of infection or comparator antibiotic regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective, observational studies have suggested that treatment with macrolides as part of an initial combination regimen (usually with a cephalosporin) for patients who require hospitalization is associated with decreased mortality",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shorter hospital stay than treatment with a cephalosporin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. However, the specific etiology of infection was not determined in these studies, and it is possible that the added coverage for \"atypical\" pathogens may, in part, explain the better outcomes.",
"   </p>",
"   <p>",
"    Additional retrospective or observational studies have suggested that benefit from combination therapy, which usually included a macrolide, also applies to severe community-acquired pneumonia (CAP) associated with S. pneumoniae bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The possible coexistence of atypical pathogens or the immunomodulating effect of the macrolides may, in part, be responsible for this finding. However, interpretation of these studies is subject to limitations inherent in their retrospective design. Furthermore, since only empiric therapy was evaluated, the findings are not necessarily applicable to pathogen-directed therapy, which is usually started 24 to 48 hours after initial therapy.",
"   </p>",
"   <p>",
"    A retrospective study evaluated almost 3000 Medicare patients, hospitalized from either home (75 percent) or a nursing home (25 percent, now considered \"healthcare-associated pneumonia\") with bacteremic CAP due to one of several pathogens, with S. pneumoniae the most common (38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/58\">",
"     58",
"    </a>",
"    ]. The use of a macrolide (as part of combination therapy), but not a fluoroquinolone (usually monotherapy), was associated with a reduced 30-day mortality. There was a trend towards improved survival with longer courses of the macrolide (eg, &gt;96 hours versus 24 hours); the authors speculated the benefit was related to the immunomodulating effect of the macrolides.",
"   </p>",
"   <p>",
"    Another observational study of patients with pneumonia requiring care in the intensive care unit (ICU) found that patients with CAP and shock who were treated with combination antibiotic therapy (58 percent with a third-generation cephalosporin plus a macrolide), compared to those treated with monotherapy (42 percent fluoroquinolone), had a higher 28-day in-ICU survival (HR 2.69, 95% CI 1.09-2.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/59\">",
"     59",
"    </a>",
"    ]. Survival was not different between combination therapy and monotherapy in ICU patients without shock. Other observational or retrospective studies have not shown an advantage of combination compared with monotherapy for CAP associated with S. pneumoniae with or without bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, a prospective, randomized trial should be performed to test whether outcomes of S. pneumoniae are better for patients treated with a combination of a macrolide and a cephalosporin, compared to a cephalosporin alone, especially since mortality risk seems to depend heavily upon underlying conditions and risk score at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg every 12 hours) was compared with combination therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    200 mg every 12 hours and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    1 g every 8 hours) in a multinational trial of 398 patients with CAP requiring ICU care, but who required neither vasopressors nor mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/21\">",
"     21",
"    </a>",
"    ]. In this trial, clinical success rates were the same for both regimens (79 versus 80 percent); these results are not generalizable to patients with shock. An accompanying editorial notes that, although the numbers were small, more patients treated with monotherapy failed a test of cure (7 of 29, compared to 1 of 27 in the combination group) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE AND CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of drug-resistant Streptococcus pneumoniae (DRSP) has made the empiric treatment of community-acquired pneumonia (CAP) more difficult.",
"   </p>",
"   <p>",
"    Drug resistant infection should be considered in communities where the prevalence of DRSP is known to be appreciable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for drug-resistant S. pneumoniae in adults include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      Beta-lactam, macrolide, or fluoroquinolone therapy within the past three to six months",
"     </li>",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Medical comorbidities",
"     </li>",
"     <li>",
"      Immunosuppressive illness or therapy",
"     </li>",
"     <li>",
"      Exposure to a child in a day care center",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recent therapy or a repeated course of therapy with beta-lactams, macrolides, or fluoroquinolones is a risk factor for pneumococcal resistance to the same class of antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/66,67,69-71\">",
"     66,67,69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Outcomes with discordant drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical relevance of DRSP for pneumonia treatment is controversial and has been the subject of several reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. There are few well-controlled studies examining the impact of discordant therapy, which refers to treatment of an infection with an antimicrobial agent to which the causative organism has demonstrated in vitro resistance. The available data suggest that the impact of discordant therapy appears to vary with antibiotic class and possibly with specific agents within a class.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Beta-lactam resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies suggest that current levels of beta-lactam resistance do not cause treatment failures for patients with CAP when appropriate agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ) and doses are used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/72-74,77,78\">",
"     72-74,77,78",
"    </a>",
"    ]. In 2008, the Clinical Laboratory Standards Institute increased the MIC breakpoint for susceptibility of pneumococcal isolates in non-meningitis infections to 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63881 \" href=\"UTD.htm?16/13/16605\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis that included 10 studies examined the association between penicillin non-susceptible pneumococcus and short-term mortality in hospitalized patients with pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/80\">",
"     80",
"    </a>",
"    ]. Although a significant difference in mortality rate was found (19.4 compared to 15.7 percent in the penicillin non-susceptible and the penicillin susceptible groups, respectively), these study results have been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/81\">",
"     81",
"    </a>",
"    ]. Comorbidities may be higher in patients with non-susceptible organisms, and the use of concordant or discordant therapy did not differentially affect survival.",
"   </p>",
"   <p>",
"    Discordant therapy for pneumococcal infection may be a specific problem for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    . A prospective, international, observational study of 844 patients with pneumococcal bacteremia found that patients who were infected with cefuroxime-resistant pneumococci and were treated with cefuroxime had a significantly higher mortality rate (36 versus 6 percent with cefuroxime concordance) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/82\">",
"     82",
"    </a>",
"    ]. On the other hand, discordant therapy involving penicillins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    did not result in a significantly higher mortality rate.",
"   </p>",
"   <p>",
"    Treatment of beta-lactam resistant S. pneumoniae is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Macrolide resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macrolide class includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . Macrolide resistance occurs via two major mechanisms: methylation of a ribosomal target encoded by the erm gene, and efflux of the macrolides by cell membrane protein transporter, encoded by the mef gene (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H3#H3\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Resistance'",
"    </a>",
"    ). S. pneumoniae strains with mef are often resistant at a lower MIC (generally 1 to 16",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    than erm strains [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/83\">",
"     83",
"    </a>",
"    ]. A high correlation has been noted between macrolide resistance and treatment with a macrolide agent within the prior three months (39 versus 8 percent with no prior use of macrolides in the past three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America and American Thoracic Society guidelines for the treatment of CAP use a 25 percent rate of high-level (&ge;16",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    macrolide resistance of pneumococcal isolates as the threshold at which this class should not be used for empiric monotherapy of CAP in patients not requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/1\">",
"     1",
"    </a>",
"    ]. However, one group reported that macrolide failures were significantly more common among patients with pneumococcal bacteremia with isolates exhibiting an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    MIC of &ge;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    irrespective of the mechanism of resistance or the degree of elevation of erythromycin MIC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, a study from the same group used a theoretical model linking the prevalence of pneumococcal resistance to macrolides with patient outcomes and found that using the proposed 25 percent rate of high-level resistance, which excludes low-level resistance, may result in excess rates of morbidity (3.3 percent for prolonged illness) and mortality (1.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/84\">",
"     84",
"    </a>",
"    ]. Thus, the rates of pneumococcal resistance at which macrolides should be used for empiric therapy of CAP in outpatients may need to be reassessed. In a large surveillance study of 14,934 isolates of S. pneumoniae collected in the United States from 1998 through 2009, the percent of isolates susceptible to erythromycin (MIC &le;0.25",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    decreased from 82.2 to 60.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have found an increased risk of macrolide failure in patients with CAP due to a macrolide-resistant S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/67,86-89\">",
"     67,86-89",
"    </a>",
"    ]. This effect was independent of the underlying resistance mechanism or of the degree of elevation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    MIC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/67\">",
"     67",
"    </a>",
"    ]. Thus, monotherapy with a macrolide should be avoided in treatment of CAP patients with known recent use of these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    is not effective against Haemophilus influenzae. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are approved for pneumonia due to H. influenzae. Because azithromycin is more effective in vitro against most strains of H. influenzae than clarithromycin, azithromycin is preferred for outpatients with comorbidities such as chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fluoroquinolone resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the United States prevalence of pneumococcal resistance to the newer fluoroquinolones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) remains low (below three percent), the rate of resistance has increased markedly in some countries. Moxifloxacin and gemifloxacin are more active against pneumococci in vitro than levofloxacin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/90\">",
"     90",
"    </a>",
"    ], although gemifloxacin has not been widely used. Prior fluoroquinolone use is a risk factor for fluoroquinolone-resistant S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of fluoroquinolones for CAP in patients with tuberculosis (TB) has been associated with a delay in diagnosis, increase in resistance, and poor outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. In a study of 428 patients with pulmonary TB, 74 (17 percent) had received at least one fluoroquinolone prescription within the six months prior to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/94\">",
"     94",
"    </a>",
"    ]. Patients who were prescribed a single course of fluoroquinolone were not more likely to have fluoroquinolone-resistant Mycobacterium tuberculosis. However, patients who received multiple fluoroquinolone prescriptions were more likely to have fluoroquinolone-resistant M. tuberculosis compared with those who received only one prescription (15 versus 0 percent, odds ratio 11:4). As pointed out by the authors and in an accompanying editorial, clinicians should perform appropriate diagnostic tests before prescribing fluoroquinolones to patients who are at risk for or have signs of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/94,96\">",
"     94,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Telithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    is a ketolide related to the macrolides. Although it has been used for the treatment of mild-to-moderate CAP, including multidrug resistant strains of S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/97,98\">",
"     97,98",
"    </a>",
"    ], and its effectiveness in CAP has been demonstrated in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/99,100\">",
"     99,100",
"    </a>",
"    ], severe hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/101\">",
"     101",
"    </a>",
"    ], visual disturbances, serious exacerbation of myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/102\">",
"     102",
"    </a>",
"    ], and loss of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/103\">",
"     103",
"    </a>",
"    ] have been reported.",
"   </p>",
"   <p>",
"    A 2006 federal advisory panel in the United States concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    should be a secondary alternative to other antimicrobial drugs. The United States Food and Drug Administration strengthened label warnings regarding the above side effects in February 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We feel",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    is most appropriately considered as an option for therapy if the patient has risk factors for macrolide-resistant pneumococci. The risk-benefit ratio should be carefully weighed by each prescriber and telithromycin should NOT be prescribed in patients with known liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link&amp;anchor=H13#H13\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\", section on 'Ketolides'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H12#H12\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Warnings about telithromycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other antibiotics for DRSP and MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is usually not required for the treatment of CAP, even when DRSP may be the pathogen. Indications for vancomycin include patients with possible accompanying pneumococcal meningitis and when MRSA is the suspected microorganism. Although many strains of community-associated MRSA are susceptible to other non-beta-lactam antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , there are no clinical studies to define appropriate antimicrobial treatment for these infections.",
"   </p>",
"   <p>",
"    Other agents with in vitro activity against DRSP and MRSA include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    . In a randomized, double-blind trial that compared linezolid to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for the treatment of hospital-acquired pneumonia (HAP) or healthcare-associated pneumonia (HCAP) due to proven MRSA, the end of study success rate was 58 percent for linezolid and 47 percent for vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/105\">",
"     105",
"    </a>",
"    ]. Linezolid was noninferior and statistically superior to vancomycin in end of treatment clinical outcome, and microbiologic outcome at end of treatment and end of study, although there was no significant difference in mortality. One caveat is that the patients in this trial had HAP or HCAP rather than CAP, and it is not clear whether these findings would apply to CAP caused by MRSA which is more likely to be associated with the USA 300 strain and associated virulence factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=see_link\">",
"     \"Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is active in vitro against DRSP and MRSA, but should not be used to treat CAP since this agent is inactivated by surfactant and has been associated with clinical failure in patients with CAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few well-controlled studies have evaluated the optimal duration of therapy for patients with community-acquired pneumonia (CAP), whether treated as outpatients or inpatients. Duration is difficult to define, since some antibiotics are administered for a short time, yet have a long half&ndash;life at respiratory sites of infection (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ). Most patients become clinically stable within three to four days of starting antibiotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/106-108\">",
"     106-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the available data, we agree with the Infectious Diseases Society of",
"    <span class=\"nowrap\">",
"     America/American",
"    </span>",
"    Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ATS)",
"    </span>",
"    guidelines that patients with CAP should be treated for a minimum of five days; because of the prolonged half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , a shorter duration may be indicated for this agent. Two meta-analyses support this recommendation. The first meta-analysis, which included 15 randomized controlled trials of almost 2800 patients with mild to moderate CAP, found comparable clinical outcomes with less than seven days compared to more than seven days of antimicrobial therapy; only two of these trials were limited to hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent meta-analysis evaluated five randomized trials of adult outpatients and inpatients with CAP not requiring care in the intensive care unit (ICU) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/110\">",
"     110",
"    </a>",
"    ]. No differences were found in clinical or microbiological outcomes between short (3 to 7 days) and long (7 to 10 days) regimens.",
"   </p>",
"   <p>",
"    Treatment trials using a variety of antibiotics have used different durations of therapy, as illustrated in the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      has been used as monotherapy for 7 to 10 days in patients initially hospitalized (intravenously for the first two to three days with the option of changing to oral therapy to complete the course) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/30,111\">",
"       30,111",
"      </a>",
"      ]; and for one dose (using the 2 g microsphere formulation) to three or five days as oral therapy in outpatients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The anti-pneumococcal fluoroquinolones (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      ) have been used for 5 to 14 days in inpatients and outpatients with CAP, with most patients having a good clinical response within 2 to 3 days. Using a higher dose of a levofloxacin may decrease the duration of therapy; 750 mg for 5 days was as effective as 500 mg for 10 days and was associated with a more rapid resolution of fever [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/112\">",
"       112",
"      </a>",
"      ]. Gemifloxacin for five days was found to be as effective as seven days for the treatment of mild-to-moderate CAP in a randomized, multicenter double-blind trial [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial that included 186 inpatients with mild to moderate-severe CAP (Pneumonia Severity Index score &le;110) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?43/42/44705?source=see_link\">",
"       calculator 1",
"      </a>",
"      ), patients who had improved substantially after an initial three days' treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      were randomly assigned to receive oral amoxicillin or placebo three times daily for an additional five days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/33/29210/abstract/108\">",
"       108",
"      </a>",
"      ]. In the three and eight day treatment groups, there was no difference in clinical success rates at day 10 (93 percent for both groups) or day 28 (90 versus 88 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for the duration of therapy in ambulatory and hospitalized patients with CAP are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\", section on 'Treatment duration and response'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice of empiric antibiotic regimens for the treatment of community-acquired pneumonia (CAP), from an expanding list of drug categories and specific antibiotics, is based on the likelihood of a specific pathogen, severity of illness, and known community susceptibilities as well as safety. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic classes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific recommendations for the treatment of patients with CAP are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies comparing newer fluoroquinolones with beta-lactams, with or without a macrolide, have shown equivalent or superior response for patients treated with fluoroquinolones. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fluoroquinolones versus beta-lactams'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fluoroquinolones are known to cause prolongation of the QT interval.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      have both been associated ventricular arrhythmias and have comparable cardiac safety profiles in elderly patients requiring hospitalization for treatment of CAP. Clinical outcomes have been comparable with respect to cure rates, but moxifloxacin has been associated with a faster time to becoming afebrile. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fluoroquinolone versus fluoroquinolone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macrolides are effective as monotherapy in outpatients with pneumonia. However, most patients had mild infections, and these studies were performed at a time when the prevalence of macrolide-resistant Streptococcus pneumoniae was lower than it is currently. Like the fluoroquinolones, the macrolides have also been associated with prolongation of the QT interval. They have also been associated with a small increased risk of cardiovascular death. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Macrolides versus other drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Macrolide resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination therapy with a macrolide plus a third-generation cephalosporin, compared to a cephalosporin alone, decreased mortality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hospital stay for patients with CAP requiring hospitalization. Similar findings have been observed for combination therapy of a beta-lactam and a macrolide compared to a beta-lactam alone in S. pneumoniae bacteremia and severe CAP. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of antibiotic therapy for CAP is unknown. Studies suggest that a minimum of five days of therapy using respiratory fluoroquinolones (shorter for some regimens of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      ) for uncomplicated CAP is associated with good outcomes. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/1\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/2\">",
"      Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/3\">",
"      Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/4\">",
"      Read RC. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. J Infect 1999; 39:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/5\">",
"      Chow JW, Yu VL. Antibiotic studies in pneumonia. Pitfalls in interpretation and suggested soluions. Chest 1989; 96:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/6\">",
"      Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/7\">",
"      Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/8\">",
"      Spellberg B, Talbot GH, Brass EP, et al. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis 2008; 47 Suppl 3:S249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/9\">",
"      Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999; 159:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/10\">",
"      Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010; 35:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/11\">",
"      Teh B, Grayson ML, Johnson PD, Charles PG. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Clin Microbiol Infect 2012; 18:E71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/12\">",
"      File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/13\">",
"      Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/14\">",
"      Finch R, Sch&uuml;rmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/15\">",
"      Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/16\">",
"      Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. Clin Infect Dis 1998; 26:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/17\">",
"      O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40 Suppl A:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/18\">",
"      Tr&eacute;moli&egrave;res F, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/19\">",
"      Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/20\">",
"      Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/21\">",
"      Leroy O, Saux P, B&eacute;dos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/22\">",
"      Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clin Infect Dis 2008; 46:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/23\">",
"      Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 60:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/24\">",
"      Moola S, Hagberg L, Churchyard GA, et al. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999; 116:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/25\">",
"      Lode H, Aronkyto T, Chuchalin AG, et al. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2004; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/26\">",
"      Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/27\">",
"      File TM Jr., Larsen LS, Fogarty LM, et al. Safety and efficacy of sequential (IV to po) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Today's Therapeutic Trends 2001; 19:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/28\">",
"      Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/29\">",
"      Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128:3398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/30\">",
"      Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/31\">",
"      Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/32\">",
"      O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/33\">",
"      Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 1998; 10:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/34\">",
"      Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents 2004; 24:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/35\">",
"      Sch&ouml;nwald S, Kuzman I, Oreskovi K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study. Infection 1999; 27:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/36\">",
"      Azithromycin extended-release (Zmax) for sinusitis and pneumonia. Med Lett Drugs Ther 2005; 47:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/37\">",
"      Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/38\">",
"      D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother 2005; 49:4035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/39\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/40\">",
"      Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis 2012; 55 Suppl 3:S181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/41\">",
"      Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012; 55 Suppl 3:S187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/42\">",
"      Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis 2012; 55 Suppl 3:S194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/43\">",
"      Farrell DJ, Castanheira M, Mendes RE, et al. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis 2012; 55 Suppl 3:S206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/44\">",
"      File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/45\">",
"      File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55 Suppl 3:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/46\">",
"      Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/47\">",
"      Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/48\">",
"      Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61:329.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed September 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/50\">",
"      Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/51\">",
"      Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/52\">",
"      Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/53\">",
"      Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/54\">",
"      Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997. Chest 2001; 119:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/55\">",
"      Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/56\">",
"      Mart&iacute;nez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/57\">",
"      Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/58\">",
"      Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/59\">",
"      Rodr&iacute;guez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/60\">",
"      Dwyer R, Ortqvist A, Aufwerber E, et al. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/61\">",
"      Chokshi R, Restrepo MI, Weeratunge N, et al. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007; 26:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/62\">",
"      Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/63\">",
"      File TM Jr, Mandell LA. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis 2003; 36:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/64\">",
"      Torres A. Monotherapy in severe community-acquired pneumonia: is it worthy? Chest 2005; 128:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/65\">",
"      Ramsdell J, Narsavage GL, Fink JB, American College of Chest Physicians' Home Care Network Working Group. Management of community-acquired pneumonia in the home: an American College of Chest Physicians clinical position statement. Chest 2005; 127:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/66\">",
"      Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/67\">",
"      Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/68\">",
"      Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998; 26:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/69\">",
"      Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/70\">",
"      Clavo-S&aacute;nchez AJ, Gir&oacute;n-Gonz&aacute;lez JA, L&oacute;pez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/71\">",
"      Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/72\">",
"      Mandell LA. Introduction: clinical relevance of antimicrobial resistance. Semin Respir Infect 2001; 16:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/73\">",
"      Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002; 15:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/74\">",
"      Falagas ME, Siempos II, Bliziotis IA, Panos GZ. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 2006; 81:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/75\">",
"      Fuller JD, McGeer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis 2005; 24:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/76\">",
"      File TM Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006; 12 Suppl 3:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/77\">",
"      File Jr TM. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/78\">",
"      Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/79\">",
"      MIC Interpretive Standards for S. pneumoniae. Clinical Laboratory Standards Institute (CLSI) 2008; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/80\">",
"      Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/81\">",
"      File TM Jr, Tan JS, Boex JR. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. Clin Infect Dis 2006; 42:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/82\">",
"      Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/83\">",
"      Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/84\">",
"      Daneman N, Low DE, McGeer A, et al. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008; 46:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/85\">",
"      Jones RN, Sader HS, Moet GJ, Farrell DJ. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010; 68:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/86\">",
"      Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/87\">",
"      Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/88\">",
"      Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/89\">",
"      Iannini PB, Paladino JA, Lavin B, et al. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother 2007; 19:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/90\">",
"      From the Food and Drug Administration. JAMA 2000; 283:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/91\">",
"      Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/92\">",
"      Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/93\">",
"      Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/94\">",
"      Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/95\">",
"      Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/96\">",
"      Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009; 48:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/97\">",
"      Yassin HM, Dever LL. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opin Investig Drugs 2001; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/98\">",
"      File TM. Telithromycin new product overview. J Allergy Clin Immunol 2005; 115:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/99\">",
"      Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/100\">",
"      Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003; 57:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/101\">",
"      Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/102\">",
"      Telithromycin (Ketek) for respiratory infections. Med Lett Drugs Ther 2004; 46:66.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2007/safety07.htm#Ketek www.fda.gov/medwatch/safety/2007/safety07.htm#Ketek (Accessed on November 21, 2011).",
"    </li>",
"    <li>",
"     Telithromycin (marketed as Ketek) Information file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107824.htm (Accessed on November 21, 2011).",
"    </li>",
"    <li>",
"     Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. LB-49, Infectious Diseases Society of America, Vancouver 2010. file://idsa.confex.com/idsa/2010/webprogram/Paper5047.html (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/106\">",
"      Men&eacute;ndez R, Torres A, Rodr&iacute;guez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/107\">",
"      Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/108\">",
"      el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/109\">",
"      Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/110\">",
"      Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. Drugs 2008; 68:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/111\">",
"      Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/112\">",
"      Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/33/29210/abstract/113\">",
"      File TM Jr, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6994 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-B88327F15F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29210=[""].join("\n");
var outline_f28_33_29210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPARISON OF SPECIFIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotic classes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Quality of studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Doxycycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fluoroquinolones versus beta-lactams",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Levofloxacin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Moxifloxacin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gemifloxacin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fluoroquinolones versus macrolides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fluoroquinolone versus fluoroquinolone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Macrolides versus other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38757748\">",
"      Ceftaroline versus ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Daptomycin versus ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tigecycline versus other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DRUG RESISTANCE AND CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Outcomes with discordant drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Beta-lactam resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Macrolide resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fluoroquinolone resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Telithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other antibiotics for DRSP and MRSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6994|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/29/39390\" title=\"figure 1\">",
"      Microbiology CAP comprehensive testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6994|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/50/40751\" title=\"table 1\">",
"      Microbiology CAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/18/8495\" title=\"table 2\">",
"      Microbiology CAP site of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/13/16605\" title=\"table 3\">",
"      Susceptibility of pneumococci",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?43/42/44705?source=related_link\" title=\"calculator 1\">",
"      Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=related_link\">",
"      Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_33_29211="Skin chromophores";
var content_f28_33_29211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common chromophore targets in skin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chromophore",
"       </td>",
"       <td class=\"subtitle1\">",
"        Light absorption range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DNA, RNA, proteins",
"       </td>",
"       <td>",
"        Ultraviolet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxyhemoglobin",
"       </td>",
"       <td>",
"        Blue-green &gt; yellow &gt;&gt; near infrared",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red tattoo ink",
"       </td>",
"       <td>",
"        Green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Green tattoo ink",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aminolevulinic acid",
"       </td>",
"       <td>",
"        Red, blue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanin",
"       </td>",
"       <td>",
"        Ultraviolet &gt; visible light &gt;&gt; near infrared",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Black tattoo ink",
"       </td>",
"       <td>",
"        Visible &amp; near infrared",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deoxyhemoglobin",
"       </td>",
"       <td>",
"        Near infrared",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sebaceous gland",
"       </td>",
"       <td>",
"        Near infrared",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat (adipocytes)",
"       </td>",
"       <td>",
"        Near infrared",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water",
"       </td>",
"       <td>",
"        Infrared",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29211=[""].join("\n");
var outline_f28_33_29211=null;
var title_f28_33_29212="Nonoral Rx sexual dysfunction";
var content_f28_33_29212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suppositories, injections, and devices for treatment of male sexual dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method of use and effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages and limitations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usage pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Suppository",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprostadil intraurethral pellet",
"       </td>",
"       <td>",
"        Muse",
"       </td>",
"       <td>",
"        <p>",
"         Alprostadil (prostaglandin E1) in gel form delivered by applicator into meatus of penis.",
"        </p>",
"        Causes vasodilation by direct vascular smooth muscle relaxation allowing blood flow and entrapment in penis.",
"       </td>",
"       <td>",
"        <p>",
"         Less invasive than intracavernosal injections, but also less effective. Can be used twice daily.",
"        </p>",
"        Not recommended with pregnant partners.",
"       </td>",
"       <td>",
"        Inserted 5 to 10 minutes before sex. Effects last up to 1 hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Penile injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprostadil",
"       </td>",
"       <td>",
"        <p>",
"         Caverject",
"        </p>",
"        Edex",
"       </td>",
"       <td>",
"        Prostaglandin E1 injected into base of penis. Causes smooth muscle relaxation in corpus cavernosae.",
"       </td>",
"       <td>",
"        <p>",
"         Effective in 50 to 85 percent of cases.",
"        </p>",
"        Disadvantages include dislike of penile self-injection, pain at injection site, requires reconstitution and sterile technique, not for use more than three times per week or more than once per 24 hours. Bleeding risk with anticoagulants. Priapism occurs uncommonly.",
"       </td>",
"       <td>",
"        Inject 10 to 20 minutes before sex. Erections may last over an hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasoactive intestinal peptide (VIP, aviptadil) and phentolamine",
"       </td>",
"       <td>",
"        Invicorp (not available in US)",
"       </td>",
"       <td>",
"        Causes vasodilation by direct vascular smooth muscle relaxation allowing blood flow and entrapment in penis.",
"       </td>",
"       <td>",
"        Possibly more effective than alprostadil. Causes less pain. Priapism rare.",
"       </td>",
"       <td>",
"        Inject 10 to 20 minutes before sex. Requires stimulation to have erection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vacuum pump",
"       </td>",
"       <td>",
"        Various",
"       </td>",
"       <td>",
"        Removes air from chamber over penis, creating a vacuum and drawing blood into penile cavernosae. Elastic tourniquet at base holds blood in penis.",
"       </td>",
"       <td>",
"        One-time expense. Safe if erection not maintained more than one hour. May not be acceptable to partner. Penis is hinged at base. May interfere with ejaculation. Can cause bruising of penis.",
"       </td>",
"       <td>",
"        Inflated just before sexual activity. Erection lasts until elastic ring removed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29212=[""].join("\n");
var outline_f28_33_29212=null;
var title_f28_33_29213="Calcium blockers and MI risk";
var content_f28_33_29213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Association of short-acting calcium channel blockers with increased MI risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 249px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relative risk of myocardial infarction (MI) according to the type of antihypertensive therapy in 623 cases and 2032 controls. The relative risk was increased in patients taking any form of calcium channel blocker (CCB), an effect that was greatest with concurrent therapy with a thiazide diuretic (Tz). There was no increase in risk with a beta blocker (&beta;-blk) or an angiotensin converting enzyme inhibitor (ACEI). The right panel shows that the deleterious effect of calcium channel blocker therapy was seen only with moderate and high doses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Psaty BM, Heckbert SR, Koepsell TD, et al. JAMA 1995; 274:620.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29213=[""].join("\n");
var outline_f28_33_29213=null;
var title_f28_33_29214="Osteoporotic spinal fractures";
var content_f28_33_29214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of osteoporotic vertebral fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the different types of vertebral fracture seen in osteoporosis. The central depression with the biconcave or codfishing appearance occurs because the edges of the vertebrae, being supported by the outer walls of the vertebrae, are stronger than the central part. In comparison, the anterior aspect of the vertebral body collapses more than the posterior aspect with a wedge fracture, while the entire vertebral body collapses down with a compression fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29214=[""].join("\n");
var outline_f28_33_29214=null;
var title_f28_33_29215="Septate uterus and vag septum";
var content_f28_33_29215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Septate uterus: complete with associated vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_33_29215=[""].join("\n");
var outline_f28_33_29215=null;
